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ABSTRACT: In this communication, we report the first example 
of dynamic kinetic asymmetric [3+2] annulation reaction of ami-
nocyclopropanes with both enol ethers and aldehydes. Using a 
copper catalyst and a commercially available bisoxazoline ligand, 
cyclopentyl- and tetrahydrofurylamines were obtained in 69-97% 
yield and up to a 98:2 enantiomeric ratio using the same reaction 
conditions. The method gives access to important enantio-
enriched nitrogen building blocks for the synthesis of bioactive 
compounds.  
The combination of nitrogen functionalities and cyclic struc-
tures is omnipresent in bioactive compounds. From the ten most 
sold pharmaceutical products based on small molecules in 2009, 
nine contain nitrogen atoms embedded in ring systems. Among 
the multitude of reported nitrogen-rich cyclic scaffolds, tetrahy-
drofurylamines and cyclopentylamines occupy a privileged posi-
tion (Figure 1). Tetrahydrofurylamines are especially important in 
the form of aminosugars, such as aminodeoxyriboses 1, which are 
at the core of DNA and many bioactive synthetic nucleoside 
analogues. Cyclopentylamines are well-represented in bioactive 
compounds, such as the bicyclic drug Ramipril (2) used to treat 
hypertension and heart diseases.1 They are also at the core of 
numerous bioactive natural products, such as the antibiotic Pac-
tamycin (3).2 A stereoselective synthetic access to tetrahydrofu-
ryl- and cyclopentylamines would be consequently highly valua-
ble in order to discover new bioactive compounds. 
 
Figure 1: Biomolecules and bioactive compounds containing an 
amino- tetrahydrofuran or cyclopentane ring. 
Since 2010, our group has examined the use of donor-acceptor 
substituted aminocyclopropanes and aminocyclobutanes for the 
synthesis of nitrogen-rich molecules (Scheme 1, A).3 This ap-
proach is particularly attractive as the nitrogen atom plays a dual 
role: it is not only an essential structural element of the product, 
but also a steering group to control regioselective ring opening 
upon release of ring strain. Despite important progress in the use 
of donor-acceptor substituted cyclopropanes,4 only few examples 
on the use of aminocyclopropanes had been reported prior to our 
own work.5 In our hands, the ring-opening of aminocyclopropanes 
was highly successful for the inter- and intramolecular addition of 
nucleophiles3a-c and the development of new annulation reactions, 
in particular for the synthesis of cyclopentyl- and tetrahydrofu-
rylamines ((1) in Scheme 1, B).3d-g The reaction of enol ethers and 
ketones using a tin catalyst was enantiospecific, whereas the iron-
catalyzed annulation of aldehydes gave racemic products. 
Scheme 1: General strategy (A), previous work (B) and 
current work (C) to access nitrogen-rich building blocks. 
 
An approach allowing the complete conversion of easily acces-
sible racemic aminocyclopropanes into enantiopure cyclopen-
tylamines –a dynamic kinetic asymmetric transformation 
(DYKAT)-6 would be much more straightforward. Such reactions 
have been realized for other classes of donor-acceptor cyclopro-
 panes in the past,7 but have never been reported in the case of 
aminocyclopropanes ((2) in Scheme 1, B). Furthermore, each 
class of substrates asked for the development of a unique catalytic 
system. The synthesis of cyclopentanes has been especially chal-
lenging. Success has been limited to the use of cyclic silyl enol 
ethers7h and indoles7m as substrates by Tang and co-workers using 
a copper catalyst with specifically designed bisoxazoline ligands.  
Herein, we would like to report the first successful dynamic ki-
netic asymmetric annulation of aminocyclopropanes with enol 
ethers and aldehydes (Scheme 1, C). Enantiomeric ratios up to 
98:2 could be achieved with complete conversion of the aminocy-
clopropane starting materials using a simple commercially availa-
ble bisoxazoline catalyst. In contrast to the only previously re-
ported method for silyl enol ethers,7h the transformation was 
especially successful for non-cyclic alkyl enol ethers. The same 
catalytic system could then be extended to the reaction of amino-
cyclopropanes with aldehydes to give tetrahydrofurylamines with 
up to a 96:4 enantiomeric ratio. To the best of our knowledge, this 
is the first report of an enantioselective catalytic system working 
for the synthesis of both cyclopentanes and tetrahydrofurans. The 
obtained enantiopure chiral building blocks will be highly useful 
for the synthesis of new nitrogen-rich bioactive compounds. 
We started our investigations by studying the annulation reac-
tion between phthalimido-substituted dimethyl ester cyclopropane 
4a and silyl enol ether 5a, as this transformation had already been 
studied in our previous work involving enantiospecific reactions 
(Scheme 2).3d,8 The catalytic system used in this work (SnCl4 at -
78 °C) was not well suited for the development of a dynamic 
kinetic asymmetric transformation, as it was highly enantiospecif-
ic at low temperature and led to decomposition at higher tempera-
ture. Consequently, a broad range of other catalysts and chiral 
ligands were examined. From these studies, copper bisoxazoline 
complex 7a emerged as the most promising catalyst, leading to 
complete conversion of cyclopropane 4a and formation of the 
cyclopentylamine 6a in a 76:24 er and a very good diastereoselec-
tivity (Scheme 2, A). Nevertheless, the enantioselectivity ob-
served was still not satisfactory and the yield of the isolated prod-
uct remained low and variable (0-50%) due to the formation of 
ring-opening side products resulting from a retro-aldol reaction. 
To address these shortcomings, extensive optimization of the 
reaction conditions, cyclopropane and enol ethers substituents, as 
well as the catalyst structure was performed (Scheme 2, B and 
C).9 No significant improvement could be obtained by changing 
solvent, temperature, concentration or catalyst loading. In contrast 
to what has been observed by Tang and co-workers,7h modifica-
tion of the diester substituents was also not successful. Finally, 
four parameters were found to be crucial to increase the selectivi-
ty and the efficiency of the reaction: 
1) Replacing the silyl group on the enol ether by an alkyl group 
(benzyl) allowed for a significant increase in yield and reproduci-
bility. The higher stability of the carbon-oxygen bond was proba-
bly essential to prevent ring-opening side reactions. 
2) The structure of the substituents on the nitrogen was essen-
tial to achieve high enantioinduction. The enantiomeric ratio was 
lower with an electron-donating methoxy substituent on the 
phthalimide (74:26, cyclopropane 4c), but increased significantly 
to 92:8 with a nitro substituent (cyclopropane 4d). However, this 
increase of enantioselectivity came at the cost of a lower diastere-
oselectivity (4:1). On the other hand, replacing the phthalimide 
group by a succinimide led to the highest enantiomeric ratio 
(95:5) without compromising the diastereoselectivity. 
3) Steric hindrance of the substituent on the ligand was another 
important factor. Best results were obtained with the commercial-
ly available bisoxazoline ligand bearing a bulky tert-butyl group. 
4) Finally, a strong counteranion effect was observed. The 
highest enantioinduction was obtained with perchlorate, whereas 
hexafluoroantimonate led to the highest diastereoselectivity. To 
obtain high enantioselectivity, it was important to exclude mois-
ture, as the blue copper aqua complex gave lower enantioinduc-
tion than the anhydrous green catalyst. 
Under the optimized conditions, the desired cyclopentylamine 
6b could finally be obtained in 94% yield and a 95:5 er with good 
diastereoselectivity (10:1), setting the stage for the investigation 
of the scope of the reaction (Scheme 1, B). 
Scheme 2: Lead result (A), optimized reaction conditions 
(B) and key parameters influencing yield and selectivity of 
the reaction. 
 
On preparative scale, cyclopentylamine 6b could be obtained in 
quantitative yield with a 96:4 er and a 7:1 dr (Table 1, entry 
1).Variation of the oxygen substituent was examined first: A 
methyl enol ether (entry 2) and a more electron-withdrawing 
trifluoroethyl group (entry 3) both worked in the annulation reac-
tion, but for the latter the diastereoselectivity of the reaction was 
lost. Variation of the aromatic substituent on the olefin gave 
comparable enantioinduction for both a meta methyl-substituted 
phenyl ring (entry 4) and a thiophene heterocycle (entry 5). The 
annulation reaction was not limited to the synthesis of tertiary 
ethers: unsubstituted benzyl ethers 5g-i also gave the desired 
products with useful selectivity (entries 6-8). On a 1 mmol scale, 
product 6g was obtained in 80% yield and a 95.5:4.5 er (entry 6). 
Achieving high selectivity in DYKAT processes is challenging 
and the catalytic system often has to be optimized for each class 
of substrates. Nevertheless, when benzaldehyde (8a) was used in 
the [3+2] annulation process with aminocyclopropane 4b, the 
DYKAT process was successful and gave the desired tetrahydro-
furylamine 9a with a 92:8 er and a 13:1 dr (Table 2, entry 1). The 
annulation reaction was successful for both electron-rich (entries 
 2 and 3) and electron-poor (entry 4) aromatic aldehydes, as well 
as for thiophene carboxaldehyde (8e) (entry 5). The best enantio-
meric ratio (96:4) was observed for the para-methoxy substituted 
benzene ring (entry 2). The reaction was not limited to aromatic 
aldehydes: both cinnamaldehyde (8f) (entry 6) and aliphatic alde-
hyde 8g (entry 7) could be used. 
Table 1. Scope of the annulation reaction with enol ethers.
a
 
Entry Enol Ether Product Yieldb/erc/drd 
1 
 
 
97% 
96:4 er 
7:1 dr 
2 
  
95% 
94.5:5.5 er 
20:1 dr 
3 
 
 
88% 
95.5:4.5 ere 
1.5:1 dr 
4 
 
 
99% 
95:5 er 
>20:1 dr 
5 
 
 
94% 
94:6 er 
8:1 dr 
6 
 
 
96% (80%)f  
96.5:3.5 
(95.5:4.5) er 
4:1 (4:1) dr 
7 
 
 
73% 
94.5:5.5 er 
5:1 dr 
8 
 
 
82% 
98:2 er 
5:1 dr 
aReaction conditions: 0.20 mmol cyclopropane 4b, 0.40 mmol 
enol ether 5, 0.02 mmol catalyst 7b, 3Å MS in dichloromethane at 
room temperature, under argon. bYield after purification by col-
umn chromatography. cDetermined by chiral phase HPLC. dDe-
termined by analysis of crude 1H NMR. eValue for major anti 
diastereoisomer, syn diastereoisomer: er = 96.5:3.5. fValues in 
brackets correspond to the results on 1 mmol scale. 
The absolute configuration of 6g was determined by X-ray crys-
tallography (S at the center next to the nitrogen atom, Figure 2). 
Interestingly, the absolute configuration is opposite to the one 
obtained by Tang and co-workers.7h,7m Although further experi-
ments will be required to establish the origin of asymmetric in-
duction, we propose a tentative stereochemical model based on 
the strong distortion from the square planar geometry in tert-
butyl-substituted bisoxazoline complexes, which is also apparent 
in the bis-aqua complex of 7b (Scheme 3).10 In complex I, formed 
from the R enantiomer of cyclopropane 4b, the distortion moves 
the cyclopropane to the upper right quadrant, opening a free path 
for fast attack of the nucleophile and affording the product with 
the observed absolute configuration. In complex II formed from 
the S enantiomer, the attack of the nucleophile is blocked by the 
tert-butyl substituents of the ligand, and is therefore slower. 
Table 2. Scope of the annulation reaction with aldehydes.
a
 
Entry aldehyde Product Yieldb/erc/drd 
1 
 
 
82% 
92:8 er 
13:1 dr 
2 
 
 
69% 
96:4 er 
>20:1 dr 
3 
 
 
84% 
93:7 er 
10:1 dr 
4 
 
 
90% 
91:9 er 
14:1 dr 
5 
 
 
97% 
95:5 er 
>20:1 dr 
6 
 
 
96% 
94:6 er 
14:1 dr 
7 
 
 
85% 
91.5:8.5 er 
13:1 dr 
aReaction conditions: 0.20 mmol cyclopropane 4b, 0.40 mmol 
aldehyde 8, 0.02 mmol catalyst 7b, 3Å MS in dichloromethane at 
room temperature, under argon. bYield after purification by col-
umn chromatography. cDetermined by chiral phase HPLC. dDe-
termined by analysis of crude 1H NMR.  
 
Figure 2: X-ray structure of compound 6g.11 
 In summary, we have reported the first example of dynamic ki-
netic asymmetric [3+2] annulation reaction of aminocyclopro-
panes. The reaction proceeded with high enantioselectivity and 
diastereoselectivity with a broad range of acyclic alkyl enol ethers 
and aldehydes using a copper catalyst with a commercially avail-
able bisoxazoline ligand. Importantly, the developed catalytic 
system could be used for both types of substrates without re-
optimization. The method is expected to be highly useful for the 
asymmetric synthesis of nitrogen-rich small organic molecules. 
Scheme 3: Stereochemical model for the reaction and X-
ray structure of complex 7b•(H2O)2.
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Experimental procedures and analytical data for all new com-
pounds. This material is available free of charge via the Internet at 
http://pubs.acs.org.  
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Figure S1: 
 
 
X-ray structure of compound 6g. The different atom locations in the benzene region result 
from the presence of two conformations in the crystal structure. As the region containing the 
stereocenters is well-defined, the assignment of the configuration is not disturbed. 
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Figure S2: 
Simplified stereochemical model for nucleophilic attack on aminocyclopropanes in 
dependence of the complex geometry. Only the CH2-CHN bond of the cyclopropane is drawn. 
The grey quadrants are blocked by the two tert-butyl groups of the ligand. 
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General Methods 
 
All reactions were carried out in oven-dried glassware under nitrogen or argon atmosphere 
with magnetic stirring, unless stated otherwise. THF, Et2O, CH3CN, toluene, hexane and 
dichloromethane were dried by passage over activated alumina under nitrogen atmosphere 
(water content < 30 ppm, Karl-Fischer titration) on an Innovative Technology Solvent 
Delivery System. All chemicals were purchased from Strem, Acros, Aldrich, Fluka, VWR, 
Aplichem or Merck and used as such unless stated otherwise. Chromatographic purification 
was performed as flash chromatography using Macherey-Nagel silica 40-63, 60 Å or using 
aluminium oxide, basic, Brockmann I purchased from Acros, using the solvents indicated as 
eluent with 0.1-0.5 bar pressure. For flash chromatography, previously distilled technical 
grade solvents were used. TLC was performed on Merck silica gel 60 F254 TLC glass plates 
or aluminium plates and visualized with UV light, and by permanganate stain, CAN stain or 
p-anisaldehyde stain followed by heating. Melting points were measured on a calibrated 
Büchi B-540 melting point apparatus using open glass capillaries. 1H- NMR spectra were 
recorded on a Brucker DPX-400 400 MHz spectrometer in CDCl3, DMSO- d6, CD2Cl2 or 
CD3OD, all signals are reported in ppm with the internal chloroform signal at 7.26 ppm, the 
internal DMSO signal at 2.50 ppm, the internal CD2Cl2 signal at 5.31 ppm, or the internal 
MeOD signal at 3.30 ppm as standard. The data are reported as follows: (s = singlet, d = 
doublet, t = triplet, q = quadruplet, qi = quintet, m = multiplet or unresolved, br = broad 
signal, coupling constant(s) in Hz, integration, interpretation). 13C-NMR spectra were 
recorded with 1H-decoupling on a Brucker DPX- 400 100 MHz spectrometer in CDCl3, 
DMSO-d6, CD2Cl2 or CD3OD, all signals are reported in ppm with the internal chloroform 
signal at 77.0 ppm, the internal DMSO signal at 39.5 ppm, the internal CD2Cl2 signal at 53.5 
ppm or the internal MeOD signal at 49.0 ppm as standard. Infrared spectra were recorded on a 
JASCO FT-IR B4100 spectrophotometer with an ATR PRO410-S and a ZnSe prisma and are 
reported as cm-1 (w = weak, m = medium, s = strong, sh = shoulder). High resolution mass 
spectrometry measurements were performed by the mass spectrometry service of ISIC at the 
EPFL on a MICROMASS (ESI) Q-TOF Ultima API. HPLC measurements were done on a 
JASCO HPLC system with an AS2055 Autosampler, a PU 2089 Pump, a UV 2075 detector 
using a CHIRALPAK IC, IB, IF or IA column from DAICEL Chemical. Optical rotations 
were measured on a polarimeter using a 10 cm cell with a Na 589 nm filter. The specific 
solvents and concentrations (in g/100 mL) are indicated. 
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Synthesis of Dimethyl-2-diazomalonate (12) 
 
 
 
Following a modified procedure,
1
 dimethylmalonate (10) (7.93 mL, 69.7 mmol, 1.00 eq), 
triethylamine (10.6 mL, 76.6 mmol, 1.10 eq) and tosyl azide (11) (15.1 g, 76.6 mmol, 1.10 eq) 
were dissolved in acetonitrile (100 mL). The solution was stirred at room temperature for 24 
hours. The solution was concentrated under reduced pressure and partitioned between 
dichloromethane (30 mL) and water (30 mL), the layers were separated and the aqueous layer 
was extracted with dichloromethane (1 x 20 mL). The organic layers were combined and 
dried over MgSO4. The crude was first filtered over a plug of silica gel (Hexane/Et2O 1:1) to 
remove most of the tosylamide formed during the reaction. Purification by column 
chromatography (Hexane/Et2O 90:10 to 80:20) afforded dimethyl-2-diazomalonate (12) as 
yellow oil which solidified under storage at 4 °C (10.4 g, 65.5 mmol, 94 % yield).  
 
Rf 0.32 (1:1 PET/Et2O).  
1H NMR (400 MHz, CDCl3) δ: 3.87 (s, 1H, OCH3).  
13C NMR (101 MHz, CDCl3) δ: 161.2, 52.42  
The characterization data for 12 correspond to the reported values.1 
 
Synthesis of N-vinyl-imides 
 
5-Methoxyisobenzofuran-1,3-dione (14) 
 
 
 
Following a modified procedure,3 a solution of 4-hydroxyphthalic acid (13) (2.00 g, 11.0 
mmol, 1.00 eq), catalytic sulfuric acid (0.10 mL, 1.9 mmol, 0.17 eq) and MeOH (20.0 mL), 
was stirred at reflux for 7 hours. under air. The solvent was removed under reduced pressure 
to afford crude dimethyl 4-hydroxyphthalate. The crude diester was dissolved in acetone (70 
mL) and reacted with potassium carbonate (7.40 g, 53.5 mmol, 5.00 eq) at 50 °C for 20 min. 
Iodomethane (1.47 mL, 23.6 mmol, 2.20 eq) was added, and the mixture was stirred at reflux 
overnight. K2CO3 was removed by filtration and the solvent was removed under reduced 
pressure to afford a colorless oil. 
 
The crude was dissolved in acetone (16.0 mL) and a 11 M solution of sodium hydroxide, 
(6.00 mL, 66.0 mmol, 6.20 eq) was added, and the solution was stirred for 6 hours. under air 
at rt. The solution was then acidified with 2 M HCl to pH 3, and concentrated under reduced 
                                                 
1 P. Wyatt, A. Hudson, J. Charmant, A. G. Orpen, H. Phetmung, Org. Biomol. Chem. 2006, 4, 2218-2232. 
2 The diazo carbon could not be detected. 
3 P. H. Mazzocchi, P. Wilson, F. Khachik, L. Klingler, S. Minamikawa, J. Org. Chem. 1983, 48, 2981. 
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pressure. Then, the crude 4-methoxyphthalic acid was dissolved into acetone (50 mL) and 
dried over MgSO4, filtered through a plug of cotton wool, and the solvent was removed in 
vacuo. The crude diacid was partitioned between 2 M NaOH (50 mL) and DCM (50 mL). The 
organic layer was extracted with NaOH 2 M (50 mL). The combined aqueous phase was 
cooled down to 0 °C and acidified with 37% HCl % to pH 3. The aqueous layer was then 
extracted five times with AcOEt (50 mL). The combined organic layers were dried over 
MgSO4 and concentrated under reduced pressure to afford the crude diacid as a light brown 
solid (1.82 g). 
 
A solution of crude 4-methoxyphthalic acid (1.82 g, 9.28 mmol, 1.00 eq) in acetic anhydride 
(25.0 mL, 266 mmol, 28.7 eq) was stirred at reflux for 21 hours. Volatiles were removed in 
vacuo to afford a dark brown solid. The crude was dissolved in DCM (50 mL) and filtered 
through fritted glass to remove solid impurities. The solution was concentrated under reduced 
pressure and dried in vacuo to afford the anhydride 14 as a light brown solid (1.62 g, 9.08 
mmol, 83% yield over 4 steps) 
 
1H NMR (400 MHz, CDCl3) δ 7.90 (dd, 1 H, J = 8.5, 0.4 Hz, Ar), 7.41 (d, 1 H, J = 2.2 Hz, 
Ar), 7.35 (dd, 1 H, J = 8.5, 2.3 Hz, Ar), 3.98 (s, 3 H, OMe).  
HRMS (ESI) calcd for C9H7O4
+ [M+H]+ 179.0339; found 179.0349.  
The 1H NMR data for 14 corresponded to the reported values.4  
 
5-Methoxyisoindoline-1,3-dione (16) 
 
 
 
Following a modified procedure,5  5-methoxyisobenzofuran-1,3-dione (14) (1.58 g, 8.84 
mmol, 1.00 eq) and formamide (15) (35.0 mL, 880 mmol, 100 eq) were divided between four 
20 mL microwave vials sealed with a microwave cap. The mixture was stirred at rt until the 
product was completely dissolved, then heated 2 times at 200 °C for 30 sec with 10 sec pre-
stirring, using Biotage Initiator 2.0 microwave reactor. The mixture was cooled to 0 °C to 
induce crystallization and cold water (10 mL) was added into each vial. The obtained solid 
was filtrated over filter paper, washed with water (15 mL) and hexanes (20 mL) and dried 
under reduced pressure to afford 5-methoxyisoindoline-1,3-dione (16) as a beige solid (982 
mg, 5.54 mmol, 63% yield) which was used without further purification. 
 
1H NMR (400 MHz, CDCl3) δ 7.77 (dd, 1 H, J = 8.3, 0.4 Hz, Ar), 7.59 (br s, 1 H, NH), 7.33 
(d, 1 H, J = 2.2 Hz, Ar), 7.20 (dd, 1 H, J = 8.3, 2.3 Hz, Ar), 3.94 (s, 3 H, OMe).  
13C NMR (101 MHz, CDCl3) δ 167.8, 167.7, 165.0, 135.2, 125.4, 124.5, 120.4, 108.1, 56.2.  
HRMS (ESI) calcd for C9H8NO3
+ [M+H]+ 178.0499; found 178.0497. 
 
5-Methoxy-2-vinylisoindoline-1,3-dione (18) 
 
                                                 
4 N. J. Hinde, C. D. Hall, J. Chem. Soc., Perkin Trans. 2. 1998, 1249. 
5 K. Kacprzak, Synth. Commun. 2003, 33, 1499. 
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Following a modified procedure,6 5-methoxyisoindoline-1,3-dione (16) (980 mg, 5.53 mmol, 
1.00 eq), PdCl2 (98.0 mg, 0.553 mmol, 0.100 eq), LiCl (235 mg, 5.53 mmol, 1.00 eq, 
weighted in a glovebox) and vinyl acetate (17) (13.7 mL, 148 mmol, 26.8 eq) were heated 
under reflux for 24 hours. The mixture was cooled down to room temperature and diluted 
with DCM/MeOH 4:1 (20 mL). Activated charcoal was added and the resulting suspension 
was filtered through a pad of Celite (DCM/MeOH 4:1 100 mL) and concentrated under 
reduced pressure. Purification by silica gel chromatography (pentane/AcOEt 90:10 to 75:25) 
afforded 5-methoxy-2-vinylisoindoline-1,3-dione (18) as a colorless solid (828 mg, 4.08 
mmol, 74% yield). 
 
Rf 0.56 (6:4 Hexane/AcOEt).  
M.p. 102.2 - 105.1 °C.  
1H NMR (400 MHz, CDCl3) δ 7.76 (d, 1 H, J = 8.3 Hz, Ar), 7.32 (d, 1 H, J = 2.2 Hz, Ar), 
7.17 (dd, 1 H, J = 8.3, 2.2 Hz, Ar), 6.83 (dd, 1 H, J = 16.4, 9.9 Hz, =CH), 6.03 (d, 1 H, J = 
16.4 Hz, =CH), 4.99 (d, 1 H, J = 9.9 Hz, =CH), 3.93 (s, 3 H, OMe).  
13C NMR (101 MHz, CDCl3) δ 166.5, 166.3, 165.1, 134.4, 125.5, 124.0, 123.5, 120.6, 108.2, 
104.0, 56.3.  
IR 1779 (w), 1720 (s), 1639 (w), 1619 (w), 1493 (w), 1386 (s), 1307 (w), 1295 (w), 1021 (w).  
HRMS (ESI) calcd for C11H10NO3
+ [M+H]+ 204.0655; found 204.0662. 
 
1-Vinylpyrrolidine-2,5-dione (20) 
 
 
 
Following a modified procedure,6 succinimide (19) (1.00 g, 10.1 mmol, 1.00 eq), vinyl acetate 
(17) (25.0 mL, 270 mmol, 26.8 eq) and Na2PdCl4 (59.0 mg, 0.202 mmol, 2.00 mol%) were 
heated under reflux for 72 hours. After solvent evaporation, the crude was purified by Biotage 
(SNAP Cartridge KP-Sil 50 g, 7:3 Hexane/AcOEt) to obtain (20) as a yellow solid (1.22 g, 
9.78 mmol, 97% yield). 
 
Rf 0.17 (8:2 Hexane/AcOEt). m.p. 47.6 – 48.9 °C.  
1H NMR (400 MHz, CDCl3) δ 6.68 (dd, 1 H, J = 16.4, 9.9 Hz, =CH), 6.08 (d, 1 H, J = 16.4 
Hz, =CH), 5.06 (d, 1 H, J = 9.9 Hz, =CH), 2.72 (s, 4 H, CH2).
  
13C NMR (101 MHz, CDCl3) δ 175.4, 124.3, 106.6, 27.8.  
IR 2946 (w), 1707 (s), 1382 (s), 1307 (m), 1222 (s), 1113 (s), 974 (m), 906 (m), 821 (w). 
HRMS (ESI) calcd for C6H8NO2
+ [M+H]+ 126.0550; found 126.0621. 
 
5-Nitro-2-vinylisoindoline-1,3-dione (22) 
                                                 
6 E. Bayer, K. Geckeler, Angew. Chem. Int. Ed. Engl. 1979, 18, 533. 
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Following a modified procedure,6 5-nitrosoindoline-1,3-dione (21) (1.00 g, 5.20 mmol, 1.00 
eq), PdCl2 (92.0 mg, 0.520 mmol, 0.100 eq), LiCl (0.221 mg, 5.20 mmol, 1.00 eq, weighted in 
a glovebox) and vinyl acetate (17) (12.9 mL, 139 mmol, 26.8 eq) were heated under reflux for 
20 hours. The mixture was cooled down to room temperature and the solvent was evaporated 
under reduced pressure. The crude was purified by column chromatography using silica gel 
(Hexane/AcOEt 8:2 to 5:5) to afford 5-nitro-2-vinylisoindoline-1,3-dione (22) as a bright 
yellow solid (1.14 g, 5.23 mmol, quantitative yield). 
 
Rf  0.32 (9:1 Pentane/AcOEt).  
M.p. 144.3 - 148.6 °C.  
1H NMR (400 MHz, CDCl3) δ 8.68 (dd, 1 H, J = 2.0, 0.5 Hz, Ar), 8.63 (dd, 1 H, J = 8.1, 2.0 
Hz, Ar), 8.08 (m, 1 H, Ar), 6.88 (dd, 1 H, J = 16.4, 9.8 Hz, CH-N), 6.14 (dd, 1 H, J = 16.4, 0.5 
Hz, =CH2), 5.16 (dd, 1 H, J = 9.8, 0.4 Hz, =CH2).  
13C NMR (101 MHz, CDCl3) δ 164.5, 164.2, 152.1, 136.1, 133.1, 129.8, 125.0, 123.6, 119.2, 
106.3.  
IR 3101 (w), 3074 (w), 2924 (w), 1709 (s), 1533 (s), 1383 (s), 1341 (s), 1307 (s), 1062 (m), 
1024 (s), 915 (s). HRMS (ESI) calcd for C10H6N2O4 [M
+] 218.0328; found 218.0355. 
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Synthesis of Aminocyclopropanes 
 
General Procedure for the of Synthesis of Aminocyclopropanes 
 
 
 
Following a modified procedure,7 the corresponding N-vinyl-imide (1.00 eq) was dissolved in 
dry dichloromethane (10.0 mL) and the solution was cooled down to 0 °C with an ice/water 
bath. Then, bis[rhodium(α,α,α', α'-tetramethyl-1,3-benzenedipropionic acid)] (0.1 mol%) was 
added in one portion. A solution in dichloromethane (2.0 mL) of dimethyldiazomalonate (12) 
(1.20 eq) was added dropwise over 5 min. After the addition, the mixture was allowed to 
warm to room temperature and stirred overnight. The solvent is then removed under reduced 
pressure and the crude is directly purified by column chromatography. 
 
Dimethyl 2-(1,3-dioxoisoindolin-2-yl)cyclopropane-1,1-dicarboxylate (4a)  
 
 
 
Following the general procedure, 4a was synthesized starting from N-vinyl-phthalimide (2.50 
g, 14.4 mmol, 1.00 eq), dimethyl-diazomalonate (12) (2.74 g, 17.3 mmol, 1.20 eq) and 
bis[rhodium(α,α,α', α'-tetramethyl-1,3-benzenedipropionic acid)] (14.0 mg, 0.0144 mmol, 
0.100 mol%). After solvent evaporation, the residue was purified by column chromatography 
using silica gel (from 8:2 to 6:4 Hexane/AcOEt), to obtain dimethyl 2-(1,3-dioxoisoindolin-2-
yl)cyclopropane-1,1-dicarboxylate (4a) as a colorless solid (4.03 g, 13.3 mmol, 92% yield). 
 
Rf 0.34 (6:4 Hexane/AcOEt).  
M.p. 131.8 – 133.9 °C.  
1H NMR (400 MHz, CDCl3) δ 7.86 (m, 2 H, Phth), 7.75 (m, 2 H, Phth), 3.85 (s, 3 H, OMe), 
3.72 (dd, 1 H, J = 8.5, 6.6 Hz, N-CH), 3.64 (s, 3 H, OMe), 2.73 (dd, 1 H, J = 6.5, 6.5 Hz, 
CH2), 2.06 (dd, 1 H, J = 8.5, 6.4 Hz, CH2).  
13C NMR (101 MHz, CDCl3) δ 168.5, 167.8, 166.9, 134.3, 131.4, 123.5, 53.1, 53.0, 34.9, 
33.1, 19.6.  
IR 2956 (w), 1783 (w), 1727 (s), 1468 (w), 1439 (w), 1399 (m), 1329 (m), 1294 (m), 1222 
(m), 1134 (w), 909 (w), 876 (w), 720 (m). 
HRMS (ESI) calcd for C15H14NO6
+ [M+H]+ 304.0816; found 304.0811. 
The 1H NMR data for 4a corresponded to the reported values.8 
 
Dimethyl 2-(2,5-dioxopyrrolidin-1-yl)cyclopropane-1,1-dicarboxylate (4b) 
 
                                                 
7 F. Gonzalez-Bobes, M. D. B. Fenster, S. Kiau, L. Kolla, S. Kolotuchin, M. Soumeillant, Adv. Synth. Catal. 
2008, 350, 813. 
8 F. de Nanteuil, J. Loup, J. Waser, Org. Lett. 2013, 15, 3738. 
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Following the general procedure, compound 4b was synthesized starting from N-vinyl-
succinimide (20) (500 mg, 4.00 mmol, 1.00 eq), dimethyldiazomalonate (12) (300 mg, 4.80 
mmol, 1.20 eq) and bis[rhodium(α,α,α', α'-tetramethyl-1,3-benzenedipropionic acid)] (3.0 mg, 
4.0 μmol, 0.10 mol%). After solvent evaporation, the residue was purified by Biotage (SNAP 
Cartridge KP-Sil 50 g, 5:5 Hexane/AcOEt), to obtain dimethyl 2-(2,5-dioxopyrrolidin-1-
yl)cyclopropane-1,1-dicarboxylate (4b) as a yellow solid (801 mg, 3.14 mmol, 79% yield). 
 
Protocol for the synthesis of enantioenriched 4b: 
 
Following the general procedure, dimethyl 2-(2,5-dioxopyrrolidin-1-yl)cyclopropane-1,1-
dicarboxylate (4b) was synthesized starting from N-vinylsuccinimide (100 mg, 0.800 mmol, 
1.00 eq), dimethyldiazomalonate (152 mg, 0.960 mmol, 1.20 eq) using tetrakis[(S)-(-)-N-(p-
dodecylphenylsulfonyl)prolinato]dirhodium(II) (0.8 mg, 8 μmol, 1 mol%). After solvent 
evaporation, the residue was purified by flash column chromatography on silica gel (1:1 to 3:7 
Pentane/AcOEt) to obtain a yellow solid, which was washed two times with MeOH to afford 
dimethyl 2-(2,5-dioxopyrrolidin-1-yl)cyclopropane-1,1-dicarboxylate as a white solid (20 mg, 
0.078 mmol, 10% yield). 
 
er = 58:42, Chiralcel IA Hexane/iPrOH 80:20, 1 mL/min, λ = 210 nm, tr1 = 23.2 min; tr2 = 
25.8 min. 
 
Rf 0.39 (5:5 Hexane/AcOEt).  
M.p. 81.9 – 85.3 °C.  
1H NMR (400 MHz, CDCl3) δ 3.78 (s, 3 H, OMe), 3.68 (s, 3 H, OMe), 3.45 (dd, 1 H, J = 8.5, 
6.5 Hz, N-CH), 2.73-2.58 (m, 4 H, O=C-CH2), 2.45 (t, 1 H, J = 6.5 Hz, CH2), 1.93 (dd, 1 H, J 
= 8.5, 6.5 Hz, CH2).  
13C NMR (101 MHz, CDCl3) δ 176.9, 168.4, 167.2, 53.2, 53.1, 35.1, 32.7, 28.1, 19.7.  
IR 2955 (w), 1717 (s), 1439 (w), 1406 (m), 1332 (m), 1296 (m), 1216 (s), 1132 (m), 1079 
(w), 910 (s).  
HRMS (ESI) calcd for C11H14NO6
+ [M+H]+ 256.0816; found 256.0822. 
 
Dicarboxylate dimethyl 2-(5-methoxy-1,3-dioxoisoindolin-2-yl)cyclopropane-1,1-
dicarboxylate (4c) 
 
 
 
Following the general procedure, compound 4c was synthesized starting from 5-methoxy-2-
vinylisoindoline-1,3-dione (18) (0.130 g, 0.640 mmol, 1.00 eq), dimethyldiazomalonate (12) 
(0.121 g, 0.768 mmol, 1.20 eq) and bis[rhodium(α,α,α′,α′-tetramethyl-1,3-benzenedipropionic 
acid)] (0.5 mg, 0.6 µmol, 0.1 mol%). After solvent evaporation, the crude was purified by 
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Biotage (SNAP Cartridge KP-Sil 10 g, 6:4 Hexane/AcOEt), to obtain dicarboxylate dimethyl 
2-(5-methoxy-1,3-dioxoisoindolin-2-yl)cyclopropane-1,1-dicarboxylate (4c) as a colorless 
solid (176 mg, 0.528 mmol, 83% yield). 
 
Rf  0.15 (8:2 Pentane/AcOEt).  
M.p. 113.5 – 117.8 °C.  
1H NMR (400 MHz, CDCl3) δ 7.71 (d, 1 H, J = 8.3 Hz, Phth), 7.27 (d, 1 H, J = 2.2 Hz, Phth), 
7.14 (dd, 1 H, J = 8.3, 2.3 Hz, Phth), 3.90 (s, 3 H, OMe), 3.80 (s, 3 H, OMe-C=O), 3.66 (dd, 1 
H, J = 8.5, 6.6 Hz, N-CH), 3.59 (s, 3 H, OMe-C=O), 2.68 (t, 1 H, J = 6.5 Hz, CH2), 1.99 (dd, 
1 H, J = 8.5, 6.4 Hz, CH2).  
13C NMR (101 MHz, CDCl3) δ 168.7, 167.8, 167.6, 167.0, 165.0, 134.1, 125.3, 123.4, 120.4, 
108.1, 56.2, 53.2, 53.0, 35.0, 33.2, 19.7.  
IR 2955 (w), 1720 (s), 1492 (m), 1437 (m), 1397 (s), 1288 (s), 1133 (m), 1018 (w).  
HRMS (ESI) calcd for C16H16NO7
+ [M+H]+ 334.0921; found 334.0915. 
 
Dimethyl 2-(5-nitro-1,3-dioxoisoindolin-2-yl)cyclopropane-1,1-dicarboxylate (4d) 
 
 
 
Following the general procedure, compound 4d was synthesized starting from 5-nitro-2-
vinylisoindoline-1,3-dione (22) (0.500 g, 2.29 mmol, 1.00 eq), dimethyl diazomalonate (12) 
(0.544 g, 2.75 mmol, 1.20 eq) and bis[rhodium(α,α,α′,α′-tetramethyl-1,3-benzenedipropionic 
acid)] (1.7 mg, 2.3 µmol, 0.10 mol%). After solvent evaporation, the crude was purified by 
Biotage (SNAP Cartridge KP-Sil 50 g, 7:3 Hexane/AcOEt), to obtain Dimethyl 2-(5-nitro-
1,3-dioxoisoindolin-2-yl)cyclopropane-1,1-dicarboxylate (4d) as a colorless solid (712 mg, 
2.04 mmol, 89% yield). 
 
Rf  0.19 (8:2 Pentane/AcOEt).   
M.p. 113.0 – 115.8 °C.  
1H NMR (400 MHz, CDCl3) δ 8.61 (m, 2 H, Ar), 8.03 (d, 1 H, J = 8.1 Hz, Ar), 3.83 (s, 3 H, 
OMe), 3.70 (m, 1 H, CH-N), 3.62 (s, 3 H, OMe), 2.63 (m, 1 H, CH2), 2.07 (m, 1 H, CH2).  
13C NMR (101 MHz, CDCl3) δ 168.2, 167.1, 165.9, 165.6, 152.0, 135.9, 132.9, 129.6, 124.9, 
119.0, 53.3, 53.2, 35.0, 33.1, 19.7.  
IR 3110 (w), 2956 (w), 2926 (w), 2853 (w), 1726 (s), 1541 (m), 1400 (m), 1344 (s), 1222 (s), 
1130 (m).  
HRMS (ESI) calcd for C15H13N2O8
+ [M+H]+ 349.0666; found 349.0664. 
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Synthesis of Esters 
 
2,2,2-Trifluoroethyl benzoate (24) 
 
 
 
In a 250 mL round bottom flask equipped with a stirring bar, 2,2,2-trifluoroethanol (2.33 mL, 
32.3 mmol, 1.00 eq), DMAP (39.5 mg, 0.323 mmol, 0.01 eq) and pyridine (3.14 mL, 38.8 
mmol, 1.20 eq) were dissolved in diethyl ether (150 mL) while stirring. A solution of benzoyl 
chloride (23) (5.00 g, 35.6 mmol, 1.10 eq) in diethyl ether (10 mL) was added dropwise to the 
reaction mixture and the reaction was stirred at room temperature for 12 hours. A saturated 
NaHCO3 solution (100 mL) was added to the crude mixture. The two layers were separated 
and the organic layer washed with water (50 mL x 3), dried over MgSO4 and the solvent 
removed under reduced pressure. 2,2,2-trifluoroethyl benzoate (24) was purified by flash 
column chromatography on silica gel (9:1 to 8:2 Pentane/AcOEt) to obtain a colourless oil 
(3.50 g, 17.1 mmol, 53 % yield).  
 
Rf  0.8 (9:1 Pentane/Et2O).  
1H NMR (400 MHz, CDCl3) δ 8.09 - 8.07 (m, 2 H, Ar), 7.64 - 7.60 (m, 1 H, Ar), 7.50 - 7.46 
(m, 2 H, Ar), 4.71 (q, 2 H, JF-H = 8.4 Hz, CH2-CF3). 
13C NMR (101 MHz, CDCl3) δ 165.1, 134.0, 130.2, 128.8, 128.5, 123.3 (q, JF-C = 277 Hz), 
60.9 (q, JF-C = 37 Hz). 
The characterization data for 24 correspond to the reported values9 
 
General Procedure for the Synthesis of Benzyl Esters 
 
 
 
In a 250 mL round bottom flask equipped with a stirring bar and a condenser, benzyl alcohol 
(25) (1.00 eq), DMAP (0.01 eq) and triethylamine (1.10 eq) were dissolved in diethyl ether 
(90 mL) while stirring. A solution of the corresponding acyl chloride (1.20 eq) in diethyl ether 
(10 mL) was added dropwise to the reaction mixture and the reaction was stirred at reflux for 
12 hours. A saturated NaHCO3 solution (100 mL) was added to the crude mixture and stirred 
for 15 min at room temperature. The two layers were separated and the organic layer was 
washed with water (50 mL x 3), dried over Na2SO4 and the solvent removed under reduced 
pressure. The esters were purified by flash column chromatography on silica gel (9:1 to 8:2 
Pentane/AcOEt). 
 
Benzyl 3-methylbenzoate (26) 
 
                                                 
9 V. Nummert, M. Piirsalu, V. Mäemets, S. Vahur, I. A. Koppel, J. Phys. Org. Chem. 2009, 22, 1155. 
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Following the general procedure, compound 26 was synthesized starting from benzyl alcohol 
(25) (1.17 g, 10.8 mmol, 1.00 eq), DMAP (13.0 mg, 0.108 mmol, 0.01 eq), triethylamine 
(1.66 mL, 11.9 mmol, 1.10 eq) and 3-methylbenzoyl chloride (2.01 g, 13.0 mmol, 1.20 eq). 
Compound 26 was obtained as a colorless oil (2.37 g, 10.5 mmol, 97% yield). 
 
Rf  0.55 (9:1 Hexane/AcOEt).  
1H NMR (400 MHz, CDCl3) δ 7.90 – 7.88 (m, 2 H, Ph), 7.47 – 7.45 (m, 2 H, Ph), 7.42 – 7.31 
(m, 5 H, Ph), 5.37 (s, 2 H, CH2), 2.40 (s, 3 H, Me). 
13C NMR (101 MHz, CDCl3) δ 166.7, 138.3, 136.3, 133.9, 130.3, 130.2, 128.7, 128.4, 128.3, 
128.3, 127.0, 66.8, 21.4. 
The characterization data for 26 correspond to the reported values.10 
 
Benzyl thiophene-2-carboxylate (27)  
 
 
 
Following the general procedure, compound 27 was synthesized starting from benzyl alcohol 
(25) (1.08 g, 10.0 mmol, 1.00 eq), DMAP (12.2 mg, 0.100 mmol, 0.01 eq), triethylamine 
(1.54 mL, 11.0 mmol, 1.10 eq) and thiophene-2-carbonyl chloride (1.76 g, 12.0 mmol, 1.20 
eq), compound 27 was obtained as a colorless oil (2.09 g, 9.58 mmol, 96% yield). 
 
Rf  0.48 (9:1 Hexane/AcOEt).  
1H NMR (400 MHz, CDCl3) δ 7.85 - 7.84 (m, 1 H, Thiophene), 7.56 (dd, 1 H, J = 5.0, 1.2 Hz, 
Thiophene), 7.46 - 7.44 (m, 2 H, Ph), 7.42 - 7.33 (m, 3 H, Ph), 7.10 (dd, 1 H, J = 4.9, 3.8 Hz, 
Thiophene), 5.36 (s, 2 H, CH2-Ph). 
13C NMR (101 MHz, CDCl3) δ 162.1, 135.9, 133.7, 133.7, 132.6, 128.7, 128.4, 128.3, 127.9, 
66.8. 
The characterization data for 27 correspond to the reported values.11 
 
  
                                                 
10 H. Liu , G. Shi , Shulei Pan , Y. Jiang ,Y. Zhang, Org. Let. 2013, 15, 4098. 
11 M. Ji, X. Wang, Y. N. Lim, Y.-W. Kang, H.-Y. Jang Eur. J. Org. Chem. 2013, 35, 7881 
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Synthesis of Enol ethers 
 
Triisopropyl((1-phenylvinyl)oxy)silane (5a) 
 
 
 
In an oven-dried flask sealed with a septum and under N2 atmosphere, acetophenone (28) 
(2.06 g, 17.1 mmol, 1.00 eq) in anhydrous THF (20 mL) is cooled down to -78 °C and a 1.9 
M solution of NaHMDS (10.8 mL, 20.5 mmol, 1.20 eq) is added dropwise. The cold bath is 
removed and the pale yellow solution is stirred for 1 hour at room temperature. The reaction is 
cooled again to 0 °C and triisopropylsilyl chloride (3.96 g, 20.5 mmol, 1.20 eq) is added 
dropwise. The reaction is stirred at room temperature for 5 hours and the solvent is directly 
removed under reduced pressure. The resulting orange oil is purified by plug or by column 
chromatography on triethylamine-deactivated silica (99% Hexane, 1% Et3N) to obtain 
Triisopropyl((1-phenylvinyl)oxy)silane 5a as a colorless oil (4.7 g, 17 mmol, 99% yield) 
 
1H NMR (400 MHz, CDCl3) δ 7.69-7.65 (m, 2 H, Ar), 7.38-7.29 (m, 3 H, Ar), 4.85 (d, 1 H, J 
= 1.8 Hz, C=CH2), 4.41 (d, 1 H, J = 1.8 Hz, C=CH2), 1.39-1.27 (m, 3 H, SiCH(CH3)2), 1.19-
1.13 (m, 18 H, SiCH(CH3)2).
 
13C NMR (101 MHz, CDCl3) δ 156.2, 138.0, 128.2, 128.1, 125.4, 90.0, 18.2, 12.9.  
The characterization data for 5a corresponded to the reported values.12 
 
General procedure for the Synthesis of disubstituted Enol Ethers. 
 
 
 
Following a slightly modified procedure,13 a round-bottom flask equipped with a magnetic 
stirrer was charged with a solution (10 to 15% in toluene) of di(cyclopenta-1,3-dien-1-
yl)dimethyltitanium (2.20 eq) in toluene,14 di(cyclopenta-1,3-dien-1-yl)titanium(IV) chloride 
(0.060 eq) and the corresponding ester (1.00 eq) under inert atmosphere. The red/orange 
mixture was heated in the dark to 80 °C for 16 hours, and then cooled to room temperature. 
Pentane (50 mL) was added to the mixture and the precipitated solids were removed by 
filtration through a basic alumina plug (Pentane/diethyl ether 9:1, 3 % Et3N) to afford a 
yellow oil. The benzyl enol ethers were purified right before use by flash column 
chromatography using basic alumina (Pentane, 3 % Et3N). 
 
(1-(Benzyloxy)vinyl)benzene (5b) 
 
                                                 
12 J-F. Zhao, B-H. Tan, T-P. Loh, Chem. Sci. 2011, 2, 349. 
13 J. F. Payack, D. L. Hughes, D. Cai, I. F. Cottrell, T. R. Verhoeven, Org. Synth. 2002, 79, 19. 
14 The Petasis reagent was synthesised according to J. F. Payack, D. L. Hughes, D. Cai, I. F. Cottrell, T. R. 
Verhoeven, Org. Synth. 2002, 79, 19.  
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Following the general procedure, compound 5b was synthesized starting from di(cyclopenta-
1,3-dien-1-yl)dimethyltitanium (19.1 g of a 10.8% solution in toluene, 9.90 mmol, 2.20 eq), 
di(cyclopenta-1,3-dien-1-yl)titanium(IV) chloride (67.2 mg, 0.270 mmol, 0.060 eq) and 
benzyl benzoate (0.955 g, 4.50 mmol, 1.00 eq) to obtain (1-(benzyloxy)vinyl)benzene (5b) as 
a colorless oil (545 mg, 2.59 mmol, 58% yield). 
 
Rf  0.8 (9:1 Hexane/Et2O).  
1H NMR (400 MHz CDCl3) δ 7.72 (ddd, J = 7.5, 3.3, 1.7 Hz, 2 H, Ar), 7.59 – 7.29 (m, 8 H, 
Ar), 5.00 (d, J = 2.1 Hz, 2 H, O-CH2-Ar), 4.79 (t, J = 2.8 Hz, 1 H, CH=C), 4.36 (t, J = 2.5 Hz, 
1 H, CH=C). 
13C NMR (101 MHz, CDCl3) δ 159.8, 137.3, 136.5, 128.6, 128.6, 128.3, 127.9, 127.5, 125.6, 
83.3, 69.9. 
IR 2432 (w), 2407 (w), 1361 (m), 1336 (s), 1161 (m), 1064 (s), 994 (s), 862 (s), 782 (m). 
HRMS (ESI) calcd for C15H14AgO
+ [M+Ag]+ 317.0090; found 317.0102 
 
1-(1-Methoxyvinyl)-4-methylbenzene (5c) 
 
 
 
Following the general procedure, compound 5c was synthesized starting from di(cyclopenta-
1,3-dien-1-yl)dimethyltitanium (24.2 g of a 12.6% solution in toluene, 14.7 mmol, 2.20 eq), 
di(cyclopenta-1,3-dien-1-yl)titanium(IV) chloride (99.0 mg, 0.400 mmol, 0.060 eq) and 2,2,2-
trifluoroethyl benzoate (1.00 g, 6.66 mmol, 1.00 eq) to obtain 1-(1-methoxyvinyl)-4-
methylbenzene (5c) as a colorless oil (537 mg, 3.63 mmol, 54% yield). 
 
Rf  0.9 (9:1 Hexane/Et2O).  
1H NMR (400 MHz, CDCl3) δ 7.78 – 7.45 (m, 2 H, Ar), 7.17 (d, J = 8.0 Hz, 2 H, Ar), 4.64 
(dd, J = 2.7, 1.0 Hz, 1 H, C=CH2), 4.20 (d, J = 2.7 Hz, 1 H, C=CH2), 3.76 (s, 3 H, OMe), 2.38 
(s, 3 H, CH3Ar). 
13C NMR (101 MHz, CDCl3) δ 161.0, 138.3, 133.7, 128.9, 128.8, 128.8, 125.3, 125.3, 125.3, 
125.3, 81.0, 55.2, 21.2. 
IR 2953 (w), 1743 (w), 1706 (w), 1644 (w), 1514 (m), 1303 (s) 1127 (s), 1047 (s), 903 (m), 
796 (s). 
HRMS (ESI) calcd for C10H12AgO
+ [M+Ag]+ 254.9934; found 254.9898. 
 
(1-(2,2,2-Trifluoroethoxy)vinyl)benzene (5d) 
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Following the general procedure, compound 5d was synthesized starting from di(cyclopenta-
1,3-dien-1-yl)dimethyltitanium (18.2 g of a 12.6% solution in toluene, 11.0 mmol, 2.20 eq), 
di(cyclopenta-1,3-dien-1-yl)titanium(IV) chloride (75.0 mg, 0.300 mmol, 0.060 eq) and 2,2,2-
trifluoroethyl benzoate (1.02 g, 5.00 mmol, 1.00 eq) to obtain (1-(2,2,2-
trifluoroethoxy)vinyl)benzene (5d) as a colorless oil (621 mg, 3.07 mmol, 61% yield). 
 
Rf  0.9 (9:1 Hexane/Et2O).  
1H NMR (400 MHz CDCl3) δ 7.65 – 7.61 (m, 2 H, Ar), 7.39 - 7.36 (m, 3 H, Ar), 4.82 (d, J = 
3.7 Hz, 1 H, CH=C), 4.31 – 4.19 (m, 3 H, CH=C, CH2-CF3). 
13C NMR (101 MHz, CDCl3) δ 159.1, 135.0, 129.2, 128.4, 125.6, 123.6 (q, J = 277 Hz). 84.3, 
65.5 (q, J = 35.8 Hz). 
IR 2374 (w), 1331 (w), 1176 (w), 1047 (s), 966 (s), 818 (m), 801 (m), 656 (s). 
HRMS (ESI) calcd for C10F3H10O
+ [M+H]+ 203.0678; found 203.0678. 
The NMR data for (XX) corresponded to the reported values.15 
 
1-(1-(Benzyloxy)vinyl)-3-methylbenzene (5e) 
 
 
Following the general procedure, compound 5e was synthesized starting from di(cyclopenta-
1,3-dien-1-yl)dimethyltitanium (17.1 g of a 10.7% solution in toluene, 8.80 mmol, 2.20 eq), 
di(cyclopenta-1,3-dien-1-yl)titanium(IV) chloride (60.0 mg, 0.240 mmol, 0.060 eq) and 
benzyl 3-methylbenzoate (0.905 g, 4.00 mmol, 1.00 eq) to obtain 1-(1-(benzyloxy)vinyl)-3-
methylbenzene (5e) as a colorless oil (450 mg, 2.01 mmol, 45% yield). 
 
Rf  0.9 (9:1 Hexane/Et2O).  
1H NMR (400 MHz CDCl3) δ 7.44 – 7.35 (m, 4 H, Ph), 7.31 (t, J = 7.5 Hz, 2 H, ArMe), 7.28 
– 7.21 (m, 1 H, Ph), 7.15 (ddd, J = 8.3, 6.1, 1.5 Hz, 1 H, ArMe), 7.05 (d, J = 7.5 Hz, 1 H, 
ArMe), 4.88 (s, 2 H, CH2-Ph), 4.64 (d, J = 2.8 Hz, 1 H, CH2=C), 4.22 (d, J = 2.8 Hz, 1 H, 
CH2=C), 2.28 (s, 3 H, Me). 
13C NMR (101 MHz, CDCl3) δ 160.1, 137.8, 137.3, 136.5, 129.4, 128.6, 128.2, 127.9, 127.6, 
126.3, 122.8, 83.2, 69.9, 21.7. 
HRMS (ESI) calcd for C16H17O
+ [M+H]+ 225.1274; found 225.1282. 
 
2-(1-(Benzyloxy)vinyl)thiophene (5f) 
 
                                                 
15 D. Vuluga, J. Legros, B. Crousse, D. Bonnet-Delpon, Eur. J. Org. Chem. 2009, 2009, 3513. 
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Following the general procedure, compound 5f was synthesized starting from di(cyclopenta-
1,3-dien-1-yl)dimethyltitanium (17.1 g of a 10.7% solution in toluene, 8.80 mmol, 2.20 eq), 
di(cyclopenta-1,3-dien-1-yl)titanium(IV) chloride (60.0 mg, 0.240 mmol, 0.060 eq) and 
benzyl thiophene-2-carboxylate (0.873 g, 4.00 mmol, 1.00 eq) to obtain 2-(1-
(benzyloxy)vinyl)thiophene (5f) (0.500 g, 4.00 mmol, 58%) as a colorless oil. 
Impurities are present in the NMR sample due to degradation of the product during analysis. 
 
Rf  0.8 (9:1 Hexane/Et2O).  
1H NMR (400 MHz, CDCl3) δ 7.58 – 7.35 (m, 6 H, Ar), 7.30 (d, J = 5.0 Hz, 1 H, Ar), 7.07 
(dd, J = 5.0, 3.7 Hz, 1 H, Ar), 5.05 (s, 2 H, Benzyl), 4.81 (d, J = 2.9 Hz, 1 H, C=CH), 4.35 (d, 
J = 3.1 Hz, 1 H, C=CH). 
13C NMR (101 MHz, CDCl3) δ 155.0, 140.4, 136.9, 128.6, 127.9, 127.3, 127.3, 125.2, 124.0, 
82.7, 69.8. 
HRMS (ESI) calcd for C13H13OS
+ [M+H]+ 217.0682; found 217.0688. 
 
General Procedure for the Synthesis of Monosubstituted Enol Ethers 
 
 
 
Following a slightly modified procedure,16 palladium(II) trifluoroacetate (0.500 mol%) and 
4,7-diphenyl-1,10-phenanthroline (0.500 mol%) were dissolved in 1-(vinyloxy)butane (29) 
(20.0 eq) in an oven-dried 20 mL vial equipped with a stirring bar to obtain a yellow solution. 
The corresponding alcohol (1.00 eq) and triethylamine (0.0750 eq) were then added to the 
solution. The flask was sealed with a microwave cap and stirred at 75 °C for 24 hours. The 
reaction was cooled to room temperature and filtrated through a plug of activated charcoal 
and eluted with hexane. The solvent was evaporated under reduced pressure to obtain the 
crude oils that were purified by a short column chromatography using deactivated silica gel (3 
% Et3N) or basic alumina and hexane as eluent. 
  
((Vinyloxy)methyl)benzene (5g) 
 
 
 
Following the general procedure, compound 5g was synthesized starting from 1-
(vinyloxy)butane (29) (12.0 mL, 92.0 mmol, 20.0 eq) and phenylmethanol (500 mg, 4.62 
mmol, 1.00 eq) with palladium(II) trifluoroacetate (7.70 mg, 23.0 µmol, 0.500 mol%), 4,7-
diphenyl-1,10-phenanthroline (7.70 mg, 23.0 µmol, 0.500 mol%), and triethylamine (35.0 mg, 
0.350 mmol, 0.0750 eq). The crude product was purified by a short column chromatography 
                                                 
16 M. Bosch, M. Schalf, J. Org. Chem. 2003, 68, 5225. 
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using deactivated silica gel (3 % Et3N) and hexane as eluent to obtain 
((vinyloxy)methyl)benzene (5g) as a colorless oil (421 mg, 3.14 mmol, 63% yield).  
 
Rf  0.9 (100 Hexane).  
1H NMR (400 MHz, CDCl3) δ 7.40-7.30 (m, 5 H, Ph), 6.57 (dd, 1 H, J = 14.3, 6.8 Hz, 
CH2=CH-O), 4.77 (s, 2 H, CH2Ph), 4.31 (dd, 1 H, J = 14.3, 1.7 Hz, CH2=CH-O), 4.09 (m, 1 
H, CH2=CH-O).  
13C NMR (101 MHz, CDCl3) δ 151.7, 136.9, 128.5, 128.0, 127.6, 87.4, 70.1. 
The characterization data for 5g corresponded to the reported values.17 
 
1-Bromo-4-((vinyloxy)methyl)benzene (5h) 
 
 
 
Following the procedure described above, compound 5h was synthesized starting from 1-
(vinyloxy)butane (29) (14.0 mL, 107 mmol, 20.0 eq) and (4-bromophenyl)methanol (1.00 g, 
5.35 mmol, 1.00 eq) with palladium(II) trifluoroacetate (8.9 mg, 27.0 µmol, 0.500 mol%), 
4,7-diphenyl-1,10-phenanthroline (8.9 mg, 27.0 µmol,0.500 mol%), and triethylamine (56.0 
µmL, 0.401 mmol, 0.075 eq). The crude product was purified by a short column 
chromatography using basic alumina and hexane as eluent to obtain 1-bromo-4-
((vinyloxy)methyl)benzene (5h) as a colorless oil (915 mg, 4.29 mmol, 80% yield). 
 
Rf  0.9 (9:1 Hexane/Et2O). 
1H NMR (400 MHz, CDCl3) δ 7.49 (d, J = 8.4 Hz, 2 H, Ar), 7.23 (d, J = 8.3 Hz, 2 H, Ar), 
6.54 (dd, J = 14.3, 6.8 Hz, 1 H, CH2=CH-O), 4.71 (s, 2 H, CH2Ar), 4.29 (dd, J = 14.3, 2.3 Hz, 
1 H, CH2=CH-O), 4.10 (dd, J = 6.8, 2.3 Hz, 1 H, CH2=CH-O). 
13C NMR (101 MHz, CDCl3) δ 151.5, 136.1, 131.8, 129.2, 122.0, 87.8, 69.4. 
IR 2359 (w), 2316 (w), 1325 (m), 1225 (m), 1091 (m), 993 (s), 895 (m), 847 (m), 684 (s). 
 
1-Nitro-4-((vinyloxy)methyl)benzene (5i) 
 
 
 
Following the procedure described above, compound 5i was synthesized starting from 1-
(vinyloxy)butane (29) (17.0 mL, 131 mmol, 20.0 eq) and (4-nitrophenyl)methanol (1.00 g, 
6.53 mmol, 1.00 eq) with palladium(II) trifluoroacetate (10.9 mg, 33.0 µmol, 0.500 mol%) 
and 4,7-diphenyl-1,10-phenanthroline (10.9 mg, 33.0 µmol, 0.500 mol%),and triethylamine 
(68.0 µmL, 0.490 mmol, 0.075 eq). The crude product was purified by a short column 
chromatography using basic alumina and hexane as eluent to obtain 1-nitro-4-
((vinyloxy)methyl)benzene (5i) as a colorless oil (973 mg, 5.43 mmol, 83% yield). 
 
Rf  0.9 (9:1 Hexane/Et2O).  
1H NMR (400 MHz, CDCl3) δ 8.23 (m, 2 H, Ar), 7.53 (m, 2 H, Ar), 6.57 (dd, 1 H, J = 14.3, 
6.8 Hz, CH=C), 4.87 (s, 2 H, OCH2Ar), 4.30 (dd, 1 H, J = 14.3, 2.5 Hz, C=CH2), 4.16 (dd, 1 
H, J = 6.8, 2.5 Hz, C=CH2). 
                                                 
17 N-A. Harada, T. Nishikata, H. Nagashima, Tetrahedron. 2012, 68, 3243. 
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13C NMR (101 MHz, CDCl3) δ 151.1, 147.5, 144.4, 127.6, 123.7, 88.2, 68.5. 
The 1H NMR data for 5i corresponded to the reported values.18 
 
Synthesis of cyclopentylamines and tetrahydrofurylamines: 
 
 
 
Synthesis of  [Cu(BOX)](X)2 7 
 
Following a modified procedure,19 an oven-dried Schlenk tube containing a magnetic 
stirrer was charged with CuCl2 (1.1 mg, 8.0 μmol, 1.0 eq), silver salt (15 μmol, 1.9 eq) and 
previously activated 3 Å MS in an inert atmosphere (N2). The flask was sealed with a septum, 
covered with aluminium foil and removed from the glovebox. Under argon atmosphere,20 0.40 
mL of a solution of the corresponding BOX ligand (9.6 μmol, 1.2 eq) in dry dichloromethane 
were added via syringe. The mixture was stirred for 3 hours at room temperature and filtrated 
under Ar into a sealed oven-dried vial using a syringe filter (regenerated cellulose, 0.2 µm), to 
obtain a bright green solution that was used for the catalysis.21  
 
 
 
General Procedure for the racemic [3+2] Annulation Reaction: 
 
A. Racemic cyclopentylamines or tetrahydrofurylamines were synthesized using 1 equivalent 
of cyclopropane with 2 equivalents of enol ether or aldehyde in presence of 20 mol% of 
scandium triflate in dry DCM at 0 °C. Conversion was followed by TLC and when full 
conversion was reached, the reaction mixture was filtered on a small silica plug. Purification 
by Preparative TLC afforded material that was submitted to HPLC. 
 
                                                 
18S. Matysiak, H.-P. Fitznar, R. Schnell, W. Pfleiderer, Helv. Chim. Acta 1998, 81, 1545. 
19 D. A. Evans, G. S. Peterson, J. S. Johnson, D. M. Barnes, K. R. Campos, K. A. Woerpel, J. Org. Chem. 1998, 63, 4541. 
20 Argon from gas cyclinder was used as using central nitrogen supply with Drierite filter gave blue complexes. 
21 Blue complex gave lower er and poorly reproducible results.  
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B. Racemic cyclopentylamines were synthesized using 1 equivalent of cyclopropane with 2 
equivalents of enol ether in presence of 20 mol% of tin tetrachloride in dry DCM at -40°C. 
Conversion was followed by TLC and when full conversion was reached, the reaction mixture 
was filtered on a small silica plug. Purification by Preparative TLC afforded material that was 
submitted to HPLC. 
 
General Procedure for the Screening of Conditions for the Catalytic Asymmetric [3+2] 
Annulation Reaction: 
 
The corresponding N-protected-aminocyclopropane22 (40.0 μmol, 1.00 eq) and freshly 
purified enol ether (50.0 μmol, 1.20 eq) were dissolved in 0.4 mL of dry dichloromethane. The 
solution was added into a sealed oven-dried vial containing a magnetic stirrer, pre-activated 3 
Å MS and 0.4 mL of the solution of the desired complex (0.01 M, 4.00 μmol, 0.1 eq). Dry 
dichloromethane was used to complete a final volume of 1.0 mL. The mixture was stirred at rt 
until full conversion was obtained as verified by TLC. The reaction was quenched by addition 
of 0.3 mL of Et3N and filtrated through a silica gel plug eluting with 5 mL of a mixture 1:1 
Hexane/AcOEt to obtain a yellowish solution. The solvent was evaporated under reduced 
pressure and the crude analyzed by 1H NMR and chiral HPLC. The yields indicated in 
Scheme 2B was obtained using trimethoxybenzene as internal standard. 
 
Dimethyl-(2S,4S)-4-(1,3-dioxoisoindolin-2-yl)-2-phenyl-2-((triisopropylsilyl)oxy) 
cyclopentane-1,1-dicarboxylate (6a) 
 
 
 
Chiralcel IA Hexane/iPrOH 95:5, 0.5 mL/min, λ = 220 nm, tr1 = 19.8 min; tr2 = 21.2 min. 
The crude of the reaction using Isopropyl-BOX/Cu(SbF6)2 complex was analyzed: er = 76:24. 
1H NMR (400 MHz, CDCl3) δ 7.87 (m, 2 H, Phth), 7.80-7.72 (m, 4 H, Phth + Ar), 7.34-7.25 
(m, 3 H, Ar), 5.29 (m, 1 H, N-C-H), 3.86 (s, 3 H, OMe), 3.81 (t, 1 H, J = 12.2 Hz, CH2), 3.47-
3.39 (m, 1H, CH2), 3.42 (s, 3H, OMe), 2.91 (dd, 1 H, J = 13.7, 8.7 Hz, CH2), 2.46 (dd, 1 H, J 
= 12.4, 6.2 Hz, CH2), 1.01-0.92 (m, 21 H, TIPS).  
13C NMR (101 MHz, CDCl3) δ 171.0, 168.7, 168.4, 141.8, 134.1, 132.0, 128.4, 128.0, 127.1, 
123.2, 87.6, 70.1, 52.4, 52.1, 47.8, 41.7, 36.2, 18.2, 18.2, 13.7.23 
The characterization data for 6a corresponded to the reported values.24 
 
Dimethyl-(2S,4S)-2-(benzyloxy)-4-(1,3-dioxoisoindolin-2-yl)-2-phenylcyclopentane-1,1-
dicarboxylate (30) 
 
                                                 
22 Dried by dissolving in benzene then removing the solvent under reduced pressure and drying in high 
vacuo. 
23 The CH3 carbons of TIPS are splitting. 
24 F. de Nanteuil, J. Waser, Angew. Chem. Int. Ed. 2011, 50, 12075. 
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Chiralcel IA Hexane/iPrOH 95:5, 1 mL/min, λ = 254 nm, tr1 = 18.3 min; tr2 = 21.1 min. 
The crude of the reaction using tert-butyl-BOX/Cu(ClO4)2 complex was analyzed: er = 78:22.  
Rf  0.7 (5:5 Pentane/AcOEt). 
M.p. 187.0 – 188.8 °C.  
1H NMR (400 MHz, CDCl3) δ 7.85 (dd, J = 5.4, 3.0 Hz, 2 H, Phth), 7.73 (dd, J = 5.5, 3.0 Hz, 
2 H, Phth), 7.66 – 7.58 (m, 2 H, Ar), 7.42 – 7.27 (m, 8 H, Ar), 5.06 (dddd, J = 11.6, 10.0, 7.5, 
6.2 Hz, 1 H, N-C-H), 4.39 (d, J = 11.7 Hz, 1 H, CH2 Benzyl), 4.08 (d, J = 11.7 Hz, 1 H, CH2 
benzyl), 3.82-3.73 (m, 1 H, CH2), 3.76 (s, 3 H, OMe), 3.65 – 3.49 (m, 1 H, CH2), 3.60 (s, 3 H, 
OMe ), 2.88 (dd, J = 14.0, 7.5 Hz, 1 H, CH2), 2.57 (dd, J = 13.1, 6.3 Hz, 1 H, CH2). 
13C NMR (101 MHz, CDCl3) δ 170.3, 168.5, 168.3, 138.2, 136.5, 134.1, 131.9, 129.2, 128.3, 
128.1, 127.3, 127.2, 126.5, 123.3, 89.8, 68.2, 63.5, 52.4, 52.2, 46.4, 36.1, 35.6. 
IR 1737 (s), 1712 (s), 1435 (w), 1379 (m), 1259 (w), 1127 (m).  
HRMS (ESI) calcd for C30H27NNaO7
+ [M+Na]+ 536.1680; found 536.1667. 
Dimethyl-(2S,4S)-2-(benzyloxy)-4-(5-methoxy-1,3-dioxoisoindolin-2-yl)-2-
phenylcyclopentane-1,1-dicarboxylate (31) 
 
 
 
Chiralcel IA Hexane/iPrOH 80:20, 1 mL/min, λ = 220 nm, tr1 = 15.4 min; tr2 = 56.1 min. 
The crude of the reaction using tert-butyl-BOX/Cu(ClO4)2 complex was analyzed: er = 74:26. 
Rf  0.8 (5:5 Pentane/AcOEt).  
M.p. 128.3 – 130.7 °C.  
1H NMR (400 MHz, CDCl3) δ 7.75 (d, J = 8.3 Hz, 1 H, Ar), 7.67 – 7.58 (m, 2 H, Ar), 7.41 – 
7.27 (m, 9 H, Ar), 7.16 (dd, J = 8.3, 2.3 Hz, 1 H, Ar), 5.10 – 4.94 (m, 1 H, N-C-H), 4.38 (d, J 
= 11.7 Hz, 1H, CH2 benzyl), 4.06 (d, J = 11.7 Hz, 1H, CH2 benzyl), 3.93 (m, 3 H, OMe), 
3.83-3.71 (m, 1 H, CH2), 3.75 (s, 3 H, OMe), 3.59 (s, 3 H, OMe), 3.57 – 3.47 (m, 1 H, CH2), 
2.86 (dd, J = 14.0, 7.5 Hz, 1 H, CH2), 2.55 (dd, J = 13.1, 6.3 Hz, 1 H, CH2). 
13C NMR (101 MHz, CDCl3) δ 170.3, 168.5, 168.1, 168.1, 164.8, 138.2, 136.6, 134.5, 129.2, 
128.3, 128.1, 127.3, 127.1, 126.5, 125.0, 123.9, 119.8, 108.0, 89.7, 68.2, 63.4, 56.1, 52.3, 
52.2, 46.4, 36.1, 35.6. 
IR 1360 (m), 1336 (s), 1263 (w), 1161 (w), 1127 (w), 1116 (w), 1115 (w), 1065 (s), 995 (m), 
967 (m), 956 (m), 863 (m), 690 (m), 689 (m). 
HRMS (ESI) calcd for C31H29NNaO8
+ [M+Na]+ 566.1785; found 566.1788. 
 
Dimethyl-(2S,4S)-2-(benzyloxy)-4-(5-nitro-1,3-dioxoisoindolin-2-yl)-2-
phenylcyclopentane-1,1-dicarboxylate (32) 
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Chiralcel IA Hexane/iPrOH 85:15, 1 mL/min, λ = 220 nm, tr1 = 33.4min; tr2 = 36.6 min. 
The crude of the reaction using tert-butyl-BOX/Cu(ClO4)2 complex was analyzed: er = 92:8). 
Rf  0.8 (5:5 Pentane/AcOEt).  
M.p. 95.5 – 98.3 °C.  
1H NMR (400 MHz, CDCl3) δ 8.82 – 8.50 (m, 2 H, Ar), 8.05 (dd, J = 8.1, 0.7 Hz, 1 H, Ar), 
7.80 – 7.57 (m, 2 H, Ar), 7.48 – 7.13 (m, 8 H, Ar), 5.06 (tdd, J = 7.7, 4.3, 2.2 Hz, 1 H, N-C-
H), 4.36 (d, J = 11.8 Hz, 1 H, CH2 benzyl), 4.10 (d, J = 11.7 Hz, 1 H, CH2 benzyl), 3.84 – 
3.67 (m, 1 H, CH2), 3.76 (s, 3 H, OMe), 3.67 – 3.44 (m, 1 H, CH2), 3.60 (s, 3 H, OMe), 2.86 
(dd, J = 14.0, 7.4 Hz, 1 H, CH2), 2.60 (dd, J = 13.1, 6.3 Hz, 1 H, CH2). 
13C NMR (101 MHz, CDCl3) δ 170.2, 168.3, 166.1, 165.8, 151.8, 138.0, 136.3, 136.2, 133.3, 
129.4, 129.1, 128.4, 128.3, 127.4, 127.3, 126.5, 124.5, 118.7, 89.8, 68.2, 63.6, 52.4, 52.3, 
47.2, 36.0, 35.6. 
IR 1393 (w), 1345 (s), 1201 (m), 1126 (w), 1115 (w), 1069 (m), 1043 (s), 972 (w), 868 (m), 
691 (m). 
HRMS (ESI) calcd for C30H26N2NaO9
+ [M+Na]+ 581.1531; found 581.1540. 
 
General Procedure for the Catalytic Asymmetric [3+2] Annulation Reaction 
 
Dimethyl 2-(2,5-dioxopyrrolidin-1-yl)cyclopropane-1,1-dicarboxylate (4b) (51.0 mg, 0.200 
mmol, 1.00 eq) and freshly purified enol ether or aldehyde (0.400 mmol, 2.00 eq) were 
dissolved in 2.0 mL of dry dichloromethane. The solution was added into a sealed oven-dried 
vial containing a magnetic stirrer, pre-activated 3 Å MS and 2.0 mL of the solution of the 
copper complex (0.01M, 0.020 mmol, 0.10 eq). Dry dichloromethane was used to complete a 
final volume of 5.0 mL. The mixture was stirred at rt until full conversion was observed by 
TLC. The reaction was quenched by addition of 0.5 mL of Et3N and filtrated through a silica 
gel plug eluting with 10 mL of a mixture of 3:7 Hexane/AcOEt. The solvent was evaporated 
under reduced pressure and the crude analyzed by 1H NMR. Purification by column 
chromatography using pentane/AcOEt (6:4 to 3:7) afforded the product as a mixture of 
diastereoisomers. In the case of the reaction with enol ether, it was possible to purify the 
major diastereomer by preparative TLC for characterization and HPLC analysis. For 
aldehydes, characterization was done directly on the obtained mixture of diastereoisomers. 
 
Racemization experiment of cyclopropane 4b 
 
Dimethyl 2-(2,5-dioxopyrrolidin-1-yl)cyclopropane-1,1-dicarboxylate (4b) (10 mg, 0.039 
mmol, 1.00 eq) was dissolved in 0.5 mL of dry dichloromethane. The solution was added into 
a sealed oven-dried vial containing a magnetic stirrer, pre-activated 3 Å MS and 2.0 mL of the 
solution of the copper complex (0.0020 M, 0.0039 mmol, 0.10 eq). Two aliquots (1 mL each) 
were taken at 30 min and 3 h after the reaction was set up. The aliquots were filtered over a 
pad of alumina, eluting with AcOEt, and were submitted to chiral HPLC analysis. 
 
er30 min = 50:50, Chiralcel IA Hexane/iPrOH 80:20, 1 mL/min, λ = 210 nm, tr1 = 23.9 min; tr2 
= 26.8 min. 
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er3h = 50:50, Chiralcel IA Hexane/iPrOH 80:20, 1 mL/min, λ = 210 nm, tr1 = 23.7 min; tr2 = 
26.4 min. 
 
Dimethyl-(2S,4S)-2-(benzyloxy)-4-(2,5-dioxopyrrolidin-1-yl)-2-phenylcyclopentane-1,1-
dicarboxylate (6b) 
 
 
 
Following the general procedure, using (1-(benzyloxy)vinyl)benzene (5b) (84.0 mg, 0.400 
mmol, 2.00 eq), dimethyl 2-(benzyloxy)-4-(2,5-dioxopyrrolidin-1-yl)-2-phenylcyclopentane-
1,1-dicarboxylate (6b) (90.3 mg, 0.194 mmol, 97 %) was obtained as a colorless solid.  
 
Crude analysis: dr = 7:1 between peaks at 5.01 (minor) and 4.67 (major). 
ermajor = 96:4, Chiralcel IA Hexane/iPrOH 80:20, 1 mL/min, λ = 210 nm, tr1 = 18.2 min; tr2 = 
24.0 min.  
[α]D25.0 -21.0 (c = 0.43, CHCl3). 
Rf 0.30 (5:5 Hexane/AcOEt).  
M.p. 90.1 – 91.7 °C.  
1H NMR (400 MHz, CDCl3) δ 7.57 – 7.41 (m, 2 H, Ar), 7.32 – 7.13 (m, 8 H, Ar), 5.01 – 4.67 
(m, 1 H, N-C-H), 4.33 (d, J = 11.7 Hz, 1H, CH2 benzyl), 4.03 (d, J = 11.7 Hz, 1H, CH2 
benzyl), 3.66 (s, 3 H, OMe), 3.56 (dd, J = 13.1, 11.6 Hz, 1 H, CH2), 3.49 (s, 3 H, OMe), 3.37 
(ddd, J = 14.0, 10.3, 0.9 Hz, 1 H, CH2), 2.71 (dd, J = 13.9, 7.2 Hz, 1 H, CH2), 2.63 (s, 4 H, 
CH2 succinimide), 2.38 (dd, J = 13.0, 6.4 Hz, 1 H, CH2). 
13C NMR (101 MHz, CDCl3) δ 177.0, 170.1, 168.3, 138.0, 136.3, 129.1, 128.2, 128.0, 127.1, 
127.0, 126.3, 89.6, 68.0, 63.2, 52.2, 52.1, 46.9, 34.9, 34.5, 28.0. 
IR 2255 (w), 1738 (w), 1704 (m), 1382 (w), 1260 (w), 1178 (w), 906 (s). 
HRMS (ESI) calcd for C26H27NNaO7
+ [M+Na]+ 488.1680; found 488.1687. 
 
Dimethyl-(2S,4S)-4-(2,5-dioxopyrrolidin-1-yl)-2-methoxy-2-(p-tolyl)cyclopentane-1,1-
dicarboxylate (6c) 
 
 
 
Following the general procedure, using 1-(1-methoxyvinyl)-4-methylbenzene (5c) (59.3 mg, 
0.400 mmol, 2.00 eq), dimethyl 4-(2,5-dioxopyrrolidin-1-yl)-2-methoxy-2-(p-
tolyl)cyclopentane-1,1-dicarboxylate (6c) (77.0 mg, 0.191 mmol, 95 %) was obtained as a 
colorless solid.  
 
Crude analysis: dr= 20:1 between peaks at 5.17 (minor) and 4.84 (major). 
ermajor = 94.5:5.5, Chiralcel IA Hexane/iPrOH 80:20, 1 mL/min, λ=220 nm, tr1 = 17.9 min; tr2 
= 22.5 min. 
[α]D25.0 15.7 (c = 0.81, CHCl3). 
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Rf  0.3 (3:7 Pentane/AcOEt).  
M.p. 97.5 - 99.0 °C.  
1H NMR (400 MHz, CDCl3) δ 7.36 (d, J = 8.3 Hz, 2 H, Ar), 7.13 (d, J = 8.1 Hz, 2 H, Ar), 
4.83 (tt, J = 11.0, 6.6 Hz, 1 H, N-CH), 3.74 (s, 3 H, OMe), 3.58 (s, 3 H, OMe), 3.54 – 3.42 (m, 
1 H, CH2), 3.36 (dd, J = 14.0, 10.7 Hz, 1 H, CH2), 2.97 (s, 3 H, Me), 2.80 – 2.60 (m, 1 H, 
CH2), 2.72 (s, 4 H, CH2 succinimide), 2.40 – 2.22 (m, 1 H, CH2), 2.36 (s, 3 H, Me).  
13C NMR (101 MHz, CDCl3) δ 177.1, 170.2, 168.5, 137.6, 133.0, 129.3, 127.8, 89.5, 67.7, 
52.2, 52.1, 49.5, 46.5, 34.9, 33.8, 28.0, 21.1. 
IR 1740 (s), 1703 (s), 1436 (w), 1399 (w), 1382 (m), 1382 (m), 1294 (w), 1276 (w), 1276 
(w), 1261 (w), 1178 (m). 
HRMS (ESI) calcd for C21H25NNaO7
+ [M+Na]+ 426.1523; found 426.1516. 
 
Dimethyl-(2S,4S)-4-(2,5-dioxopyrrolidin-1-yl)-2-phenyl-2-(2,2,2-
trifluoroethoxy)cyclopentane-1,1-dicarboxylate (6d) 
 
 
 
Following the general procedure, using (1-(2,2,2-trifluoroethoxy)vinyl)benzene (5d) (81.0 
mg, 0.400 mmol, 2.00 eq), dimethyl 4-(2,5-dioxopyrrolidin-1-yl)-2-phenyl-2-(2,2,2-
trifluoroethoxy)cyclopentane-1,1-dicarboxylate (6d) (80.4 mg, 0.176 mmol, 88 %) was 
obtained as a colorless oil.  
 
Crude analysis: dr = 1.5:1 between peaks at 5.06 (minor) and 4.75 (major). 
anti 
er = 95.5:4.5, Chiralcel IB Hexane/iPrOH 80:20, 1 mL/min, λ = 210 nm, tr1 = 14.6 min; tr2 = 
17.4 min.  
[α]D25.0 18.9 (c = 0.43, CHCl3). 
Rf  0.2 (4:6 Pentane/AcOEt).  
1H NMR (400 MHz, CDCl3) δ 7.59 – 7.43 (m, 2 H, Ar), 7.43 – 7.28 (m, 3 H, Ar), 4.97 – 4.75 
(m, 1 H, N-CH), 3.80 (s, 3 H, OMe), 3.60 (dd, J = 13.4, 11.6 Hz, 1 H, CH2), 3.56 – 3.44 (m, 1 
H, CH2-CF3), 3.53 (s, 3 H, OMe), 3.43 – 3.30 (m, 2 H, CH2 + CH2-CF3), 2.84 – 2.75 (m, 1 H, 
CH2), 2.71 (s, 4 H, CH2 succinimide), 2.24 (dd, J = 13.3, 6.4 Hz, 1 H, CH2). 
13C NMR (101 MHz, CDCl3) δ 177.0, 169.8, 167.7, 135.0, 129.0, 128.7, 127.6, 123.6 (q, J = 
278 Hz), 90.4, 67.7, 60.50 (q, J = 35 Hz), 52.4, 52.3, 46.6, 34.8, 34.6, 28.0. 
IR 1808 (m), 1771 (s), 1521 (w), 1520 (w), 1459 (w), 1355 (m), 1256 (s). 
HRMS (ESI) calcd for C21H22F3NNaO7
+ [M+Na]+ 480.1241; found 480.1243. 
 
syn 
er = 96.5:3.5, Chiralcel IA Hexane/iPrOH 90:10, 1 mL/min, λ = 220 nm, tr1 = 28.6 min; tr2 = 
31.1 min.  
[α]D25.0 -2.3 (c = 0.39, CHCl3). 
Rf  0.3 (4:6 Pentane/AcOEt).  
1H NMR (400 MHz, CDCl3) δ 7.64 – 7.52 (m, 2 H, Ar), 7.41 – 7.29 (m, 3 H, Ar), 5.20 – 5.06 
(m, 1 H, N-CH), 4.06 (dq, J = 10.2, 8.4 Hz, 1 H, CH2-CF3), 3.75 (s, 3 H, OMe), 3.61 – 3.40 
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(m, 1 H, CH2 + CH2-CF3), 3.50 (s, 3 H, OMe), 3.01 (dd, J = 15.1, 11.0 Hz, 1 H, CH2), 2.84 – 
2.67 (m, 5 H, CH2 succinimide+ CH2), 2.34 (dd, J = 12.9, 7.4 Hz, 1 H, CH2). 
13C NMR (101 MHz, CDCl3) δ 177.1, 169.3, 167.6, 135.2, 129.1, 128.4, 127.6, 124.1 (q, J = 
278 Hz), 90.7, 70.0, 60.4 (q, J = 35 Hz), 52.5, 52.1, 47.4, 36.5, 33.7, 28.0. 
IR 1737 (m), 1705 (s), 1447 (w), 1382 (w), 1279 (m), 1256 (w), 1170 (s). 
HRMS (ESI) calcd for C21H22F3NNaO7
+ [M+Na]+ 480.1241; found 480.1237. 
 
 
 
Dimethyl-(2S,4S)-2-(benzyloxy)-4-(2,5-dioxopyrrolidin-1-yl)-2-(m-tolyl)cyclopentane-1,1-
dicarboxylate (6e) 
 
 
 
Following the general procedure, using 1-(1-(benzyloxy)vinyl)-3-methylbenzene (5e) (90.0 
mg, 0.400 mmol, 2.00 eq), dimethyl 2-(benzyloxy)-4-(2,5-dioxopyrrolidin-1-yl)-2-(m-
tolyl)cyclopentane-1,1-dicarboxylate (6e) (96.0 mg, 0.199 mmol, 99%) was obtained as a 
colorless oil.  
 
Crude analysis: dr >20:1. 
er = 95:5, Chiralcel IA Hexane/iPrOH 80:20, 1 mL/min, λ = 220 nm, tr1 = 16.2 min; tr2 = 
22.1 min.  
[α]D25.0 -16.5 (c = 0.44, CHCl3). 
Rf  0.25 (4:6 Pentane/AcOEt).  
1H NMR (400 MHz, CDCl3) δ 7.37 – 7.29 (m, 4 H, Ar), 7.28 – 7.23 (m, 3 H, Ar), 7.20 (t, J = 
7.7 Hz, 1 H, Ar), 7.11 (d, J = 7.5 Hz, 1 H, Ar), 4.97 – 4.81 (m, 1 H, N-CH), 4.31 (d, J = 11.7 
Hz, 1 H, CH2 benzyl), 4.03 (d, J = 11.7 Hz, 1 H, CH2 benzyl), 3.73 (s, 3 H, OMe), 3.65 – 3.55 
(m, 1 H, CH2), 3.57 (s, 3 H, OMe), 3.44 (dd, J = 13.9, 10.4 Hz, 1 H, CH2), 2.78 (dd, J = 13.9, 
7.0 Hz, 1 H, CH2), 2.70 (s, 4 H, CH2 succinimide), 2.45 (dd, J = 13.0, 6.5 Hz, 1 H, CH2), 2.34 
(s, 3 H, Me). 
13C NMR (101 MHz, CDCl3) δ 177.1, 170.2, 168.3, 138.2, 136.5, 136.3, 130.0, 128.8, 128.3, 
127.125, 126.4, 126.2, 89.7, 68.1, 63.3, 52.2, 52.1, 46.9, 35.0, 34.6, 28.0, 21.7. 
IR 2924 (w), 1739 (m), 1703 (s), 1435 (w), 1383 (m), 1295 (w), 1259 (w), 1181 (m), 738 (w). 
HRMS (ESI) calcd for C27H29NNaO7
+ [M+Na]+ 502.1836; found 502.1845. 
 
                                                 
25 2 carbon signal overlapping.  
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Dimethyl-(2R,4S)-2-(benzyloxy)-4-(2,5-dioxopyrrolidin-1-yl)-2-(thiophen-2-
yl)cyclopentane-1,1-dicarboxylate (6f) 
 
 
 
Following the general procedure, using 2-(1-(benzyloxy)vinyl)thiophene (5f) (87.0 mg, 0.400 
mmol, 2.00 eq), dimethyl 2-(benzyloxy)-4-(2,5-dioxopyrrolidin-1-yl)-2-(thiophen-2-
yl)cyclopentane-1,1-dicarboxylate (6f) (89.1 mg, 0.189 mmol, 94%) was obtained as a 
colorless oil.  
 
Crude analysis: dr = 8:1 between peaks at 5.11 (minor) and 4.86 (major). 
ermajor = 94:6, Chiralcel IA Hexane/iPrOH 80:20, 1 mL/min, λ = 210 nm, tr1 = 27.0 min; tr2 = 
40.2 min.  
[α]D25.0 -11.8 (c = 0.44, CHCl3). 
Rf  0.2 (4:6 Pentane/AcOEt).  
1H NMR (400 MHz, CDCl3) δ 7.42 – 7.14 (m, 7 H, Ar), 6.97 (dd, J = 5.1, 3.6 Hz, 1 H, 
Thiophene), 4.86 (dddd, J = 11.9, 10.0, 7.9, 6.3 Hz, 1 H, N-CH), 4.33 (d, J = 11.4 Hz, 1H, 
CH2 benzyl), 4.14 (d, J = 11.4 Hz, 1H, CH2 benzyl), 3.79 (s, 3 H, OMe), 3.63 – 3.52 (m, 1 H, 
CH2), 3.60 (s, 3 H, OMe), 3.38 (dd, J = 13.9, 10.1 Hz, 1 H, CH2), 2.79 (dd, J = 13.9, 7.9 Hz, 1 
H, CH2), 2.70 (s, 4 H, CH2 succinimide), 2.59 (dd, J = 12.9, 6.3 Hz, 1 H, CH2). 
13C NMR (101 MHz, CDCl3) δ 177.2, 170.2, 168.5, 141.4, 138.0, 128.9, 128.3, 127.4, 126.9, 
126.6, 126.0, 87.7, 68.2, 63.9, 52.5, 52.4, 47.1, 36.8, 34.7, 28.2. 
IR 1740 (s), 1704 (s), 1435 (w), 1384 (w), 1270 (w), 1175 (m). 
HRMS (ESI) calcd for C24H25NNaO7S
+ [M+Na]+ 494.1244; found 494.1241. 
 
 
 
Dimethyl-(2R,4S)-2-(benzyloxy)-4-(2,5-dioxopyrrolidin-1-yl)cyclopentane-1,1-
dicarboxylate (6g) 
 
 
 
Following the general procedure, using ((vinyloxy)methyl)benzene (5g) (53.7 mg, 0.400 
mmol, 2.00 eq), dimethyl 2-(benzyloxy)-4-(2,5-dioxopyrrolidin-1-yl)cyclopentane-1,1-
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dicarboxylate (6g) (74.8 mg, 0.192 mmol, 96%) was obtained as a colorless solid. 
Recrystallized from isopropanol.26  
 
Crude analysis: dr= 4:1 between peaks at 3.79 (major) and 3.75 (minor). 
ermajor = 96.5:3.5, Chiralcel IA Hexane/iPrOH 80:20, 1 mL/min, λ = 210 nm, tr1 = 27.4 min; 
tr2 = 37.8 min.  
[α]D25.0 -32.7 (c = 0.43, CHCl3). 
Rf  0.3 (5:5 Pentane/AcOEt).  
M.p. 106.8 – 109.5 °C.  
1H NMR (400 MHz, CDCl3) δ 7.36 – 7.24 (m, 5 H, Ar), 5.03 – 4.82 (m, 1 H, N-C-H), 4.75 
(dd, J = 4.7, 2.7 Hz, 1 H, O-C-H), 4.59 (d, J = 11.9 Hz, 1H, CH2 benzyl) 4.49 (d, J = 11.9 Hz, 
1H, CH2 benzyl), 3.79 (s, 3 H, OMe), 3.68 (s, 3 H, OMe), 3.03 (dd, J = 14.4, 10.6 Hz, 1 H, 
CH2), 2.64 (s, 4 H, succinimide), 2.50 – 2.29 (m, 2 H, CH2), 2.15 (ddd, J = 13.4, 8.3, 2.7 Hz, 1 
H, CH2). 
13C NMR (101 MHz, CDCl3) δ 176.9, 171.0, 169.0, 138.0, 128.3, 127.6, 127.4, 83.0, 71.7, 
65.1, 52.9, 52.7, 48.0, 34.0, 33.3, 28.0. 
IR 1737 (m), 1702 (s), 1398 (w), 1397 (w), 1384 (w), 1283 (w), 1262 (w), 1175 (m), 1100 
(w). 
HRMS (ESI) calcd for C20H24NO7
+ [M+H]+ 390.1547; found 390.1554. 
 
 
 
Procedure for the Catalytic Asymmetric [3+2] Annulation Reaction on 1 mmol scale:  
 
Dimethyl 2-(2,5-dioxopyrrolidin-1-yl)cyclopropane-1,1-dicarboxylate (4b) (255 mg, 1.00 
mmol, 1.00 eq) and freshly purified enol ether 5g (268 mg, 2.00 mmol, 2.00 eq) were 
dissolved in 10.0 mL of dry dichloromethane. The solution was added into a sealed oven-dried 
vial containing a magnetic stirrer, pre-activated 3 Å MS and 10.0 mL of the solution of the 
copper complex (0.01 M, 0.100 mmol, 0.10 eq). Dry dichloromethane was used to complete a 
final volume of 25.0 mL. The mixture was stirred at rt for 2 hours and full conversion was 
observed by TLC. The reaction was quenched by addition of 1 mL of Et3N and filtrated 
through a silica gel plug eluting with 50 mL of a mixture of 3:7 Hexane/AcOEt. The solvent 
was evaporated under reduced pressure and the crude analyzed by 1H NMR. Purification by 
column chromatography using pentane/AcOEt (6:4 to 3:7) afforded dimethyl-2-(benzyloxy)-
4-(2,5-dioxopyrrolidin-1-yl)cyclopentane-1,1-dicarboxylate (6g) (311 mg, 0.800 mmol, 80%) 
as a colorless solid. 
Crude analysis: dr= 4:1 between peaks at 3.03 (major) and 3.37 (minor). 
ermajor = 95.5:4.5, Chiralcel IA Hexane/iPrOH 80:20, 1 mL/min, λ = 210 nm. 
 
Dimethyl-(2R,4S)-2-((4-bromobenzyl)oxy)-4-(2,5-dioxopyrrolidin-1-yl)cyclopentane-1,1-
dicarboxylate (6h) 
 
                                                 
26 Structure is registered in CCDC under the number CCDC 988525 
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Following the general procedure, using 1-bromo-4-((vinyloxy)methyl)benzene (5h) (85.0 mg, 
0.400 mmol, 2.00 eq), dimethyl 2-((4-bromobenzyl)oxy)-4-(2,5-dioxopyrrolidin-1-
yl)cyclopentane-1,1-dicarboxylate (6h) (68.2 mg, 0. 146 mmol, 72.8 %) was obtained as a 
colorless oil.  
 
Crude analysis: dr = 5:1 between peaks at 3.36 (minor) and 3.00 (major). 
ermajor > 94.5:5.5
27, Chiralcel IB Hexane/iPrOH 80:20, 1 mL/min, λ = 220 nm, tr1 = 26.0 min; 
tr2 = 29.6 min.  
[α]D25.0 -28.9 (c = 0.46, CHCl3). 
Rf 0.20 (4:6 Hexane/AcOEt).  
1H NMR (400 MHz, CDCl3) δ 7.44 (d, J = 8.3 Hz, 2 H, Ar), 7.13 (d, J = 8.3 Hz, 2 H, Ar), 
4.93 (dtd, J = 10.6, 8.7, 6.4 Hz, 1 H, N-C-H), 4.75 (dd, J = 4.9, 3.0 Hz, 1 H, O-C-H), 4.55 (d, 
J = 11.9 Hz, 1H, CH2 benzyl), 4.44 (d, J = 12.1 Hz, 1H, CH2 benzyl), 3.79 (s, 3 H, OMe), 
3.68 (s, 3 H, OMe), 3.00 (dd, J = 14.4, 10.6 Hz, 1 H, CH2), 2.65 (s, 4 H, CH2 succinimide), 
2.50 – 2.24 (m, 2 H, CH2), 2.13 (ddd, J = 13.5, 8.4, 3.0 Hz, 1 H, CH2). 
13C NMR (101 MHz, CDCl3) δ 176.8, 171.0, 169.0, 137.0, 131.4, 129.0, 121.4, 83.0, 71.0, 
65.0, 52.9, 52.7, 47.8, 34.1, 33.4, 28.0. 
IR 1739 (m), 1703 (s), 1397 (w), 1383 (w), 1283 (w), 1262 (w), 1261 (w), 1176 (w). 
HRMS (ESI) calcd for C20
79BrH23NO7
+ [M+H]+ 468.0652; found 468.0661. 
 
 
 
Dimethyl-(2R,4S)-4-(2,5-dioxopyrrolidin-1-yl)-2-((4-nitrobenzyl)oxy)cyclopentane-1,1-
dicarboxylate (6i) 
 
 
 
Following the general procedure, using 1-nitro-4-((vinyloxy)methyl)benzene (5i) (71.7 mg, 
0.400 mmol, 2.00 eq), dimethyl 4-(2,5-dioxopyrrolidin-1-yl)-2-((4-
                                                 
27 Due to shoulder in the peaks, separation was not complete (cf HPLC spectra). 
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nitrobenzyl)oxy)cyclopentane-1,1-dicarboxylate (6i) (71.0 mg, 0.163 mmol, 82%) was 
obtained as a colorless solid.  
 
Crude analysis: dr= 5:1 between peaks at 4.44 (minor) and 4.95 (major). 
ermajor = 98:2, Chiralcel IF Hexane/iPrOH 70:30, 1 mL/min, λ=230 nm, tr1 = 49.9 min; tr2 = 
67.0 min. 
[α]D25.0 -27.1 (c = 0.43, CHCl3). 
Rf 0.39 (5:5 Hexane/AcOEt).  
M.p. 67.9 – 70.5 °C.  
1H NMR (400 MHz, CDCl3) δ 8.23 – 8.11 (m, 2 H, Ar), 7.46 – 7.39 (m, 2 H, Ar), 4.95 (dtd, J 
= 10.5, 8.6, 6.5 Hz, 1 H, N-CH), 4.86 – 4.80 (m, 1 H, CHO), 4.72 (d, J = 13.2 Hz, 1H, CH2 
benzyl), 4.62 (d, J = 13.2 Hz, 1H, CH2 benzyl), 3.80 (s, 3 H, Me), 3.70 (s, 3 H, Me), 3.00 (dd, 
J = 14.4, 10.5 Hz, 1 H, CH2), 2.66 (s, 4 H, CH2 succinimide), 2.45 – 2.34 (m, 2 H, CH2), 2.19 
(ddd, J = 13.6, 8.7, 3.6 Hz, 1 H, CH2). 
13C NMR (101 MHz, CDCl3) δ 176.8, 170.8, 168.9, 147.3, 145.5, 127.3, 123.5, 83.4, 70.5, 
64.9, 52.9, 52.7, 47.6, 34.0, 33.5, 27.9. 
IR 1737 (m), 1703 (s), 1523 (w), 1348 (m), 1284 (w), 1177 (w). 
HRMS (ESI) calcd for C20H22N2NaO9
+ [M+Na]+ 457.1218; found 457.1232. 
 
 
Dimethyl-(2R,5R)-5-(2,5-dioxopyrrolidin-1-yl)-2-phenyldihydrofuran-3,3(2H)-
dicarboxylate (9a) 
 
 
 
Following the general procedure, using benzaldehyde (8a) (42.4 mg, 0.400 mmol, 2.00 eq), 
dimethyl 5-(2,5-dioxopyrrolidin-1-yl)-2-phenyldihydrofuran-3,3(2H)-dicarboxylate (9a) (59.2 
mg, 0. 164 mmol, 82 %) was obtained as a colorless oil.  
 
Crude analysis: dr = 13:1 between peaks at 5.35 (minor) and 5.78 (major). 
ermajor = 92:8, Chiralcel IA Hexane/iPrOH 70:30, 1 mL/min, λ = 210 nm, tr1 = 18.9 min; tr2 = 
24.3 min.  
erminor = 92:8, Chiralcel IA Hexane/iPrOH 70:30, 1 mL/min, λ = 210 nm, tr1 = 11.1 min; tr2 = 
13.0 min. 
[α]D25.0 50.9 (c = 0.49, CHCl3). 
Rf  0.4 (4:6 Pentane/AcOEt). 
1H NMR (400 MHz, CDCl3) δ 7.51 (d, J = 7.5 Hz, 2 H, Ar), 7.35 – 7.23 (m, 3 H, Ar), 5.78 
(m, 2 H, N-C-H + Ph-C-H), 4.24 – 4.05 (m, 1 H, CH2), 3.83 (s, 3 H, OMe), 3.10 (d, J = 1.7 
Hz, 3 H, OMe), 2.75 (d, J = 1.7 Hz, 4 H, CH2 succinimide), 2.45 – 2.28 (m, 1 H, CH2). 
13C NMR (101 MHz, CDCl3) δ 176.2, 170.9, 167.8, 137.5, 128.5, 128.0, 127.6, 82.5, 79.6, 
65.0, 53.4, 52.3, 33.1, 28.0. 
IR 1737 (s), 1715 (s), 1436 (w), 1384 (w), 1275 (m), 1233 (w), 1169 (w). 
HRMS (ESI) calcd for C18H20NO7
+ [M+H]+ 362.1234; found 362.1235. 
 
Dimethyl-(2R,5R)-5-(2,5-dioxopyrrolidin-1-yl)-2-(4-methoxyphenyl)dihydrofuran-
3,3(2H)-dicarboxylate (9b) 
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Following the general procedure, using 4-methoxybenzaldehyde (8b) (54.5 mg, 0.400 mmol, 
2.00 eq), dimethyl 5-(2,5-dioxopyrrolidin-1-yl)-2-(4-methoxyphenyl)dihydrofuran-3,3(2H)-
dicarboxylate (9b) (54.1 mg, 0.138 mmol, 69%) was obtained as a colorless oil.  
 
Crude analysis: dr > 20:1. 
er = 96:4, Chiralcel IC Hexane/iPrOH 80:20, 1 mL/min, λ = 220 nm, tr1 = 34.9 min; tr2 = 
38.5 min.  
[α]D25.0 17.8 (c = 0.50, CHCl3). 
Rf  0.30 (4:6 Pentane/AcOEt). 
1H NMR (400 MHz, CDCl3) δ 7.51 – 7.38 (m, 2 H, Ar), 6.94 – 6.70 (m, 2 H, Ar), 5.87 – 5.66 
(m, 2 H, N-C-H + Ph-C-H), 4.14 (dd, J = 13.1, 11.0 Hz, 1 H, CH2), 3.83 (s, 3 H, OMe), 3.78 
(s, 3 H, OMe), 3.17 (s, 3 H, OMe), 2.75 (s, 4 H, CH2 succinimide), 2.35 (dd, J = 13.1, 5.1 Hz, 
1 H, CH2). 
13C NMR (101 MHz, CDCl3) δ 176.2, 170.9, 167.8, 159.7, 129.7, 128.9, 113.3, 82.3, 79.5, 
64.9, 55.2, 53.4, 52.4, 33.0, 28.0. 
IR 1732 (s), 1708 (s), 1614 (w), 1516 (w), 1365 (m), 1274 (m), 1250 (s), 1174 (s). 
HRMS (ESI) calcd for C19H22NO8
+ [M+H]+ 392.1340; found 392.1346. 
 
Dimethyl-(2R,5R)-5-(2,5-dioxopyrrolidin-1-yl)-2-(3-methoxyphenyl)dihydrofuran-
3,3(2H)-dicarboxylate (9c) 
 
 
 
Following the general procedure, using 3-methoxybenzaldehyde (8c) (54.5 mg, 0.400 mmol, 
2.00 eq), dimethyl 5-(2,5-dioxopyrrolidin-1-yl)-2-(3-methoxyphenyl)dihydrofuran-3,3(2H)-
dicarboxylate (9c) (65.9 mg, 0.168 mmol, 84 %) was obtained as a colorless oil.  
 
Crude analysis: dr = 10:1 between peaks at 6.05 (minor) and 5.82 (major). 
er = 93:7, Chiralcel IA Hexane/iPrOH 70:30, 1 mL/min, λ = 210 nm, tr1 = 23.8 min; tr2 = 
27.2 min.  
[α]D25.0 57.8 (c = 0.47, CHCl3). 
Rf  0.4 (4:6 Pentane/AcOEt). 
1H NMR (400 MHz, CDCl3) δ 7.24 – 7.15 (m, 2 H, Ar), 7.02 (d, J = 7.6 Hz, 1 H, Ar), 6.88 – 
6.73 (m, 1 H, Ar), 5.87 – 5.68 (m, 2 H, N-C-H + Ph-C-H), 4.15 (dd, J = 13.2, 11.1 Hz, 1 H, 
CH2), 3.87 – 3.85 (m, 6 H, OMe + OMe), 3.16 (s, 3 H, OMe), 2.75 (s, 4 H, CH2 succinimide), 
2.36 (dd, J = 13.1, 5.0 Hz, 1 H, CH2). 
13C NMR (101 MHz, CDCl3) δ 176.2, 170.8, 167.7, 159.5, 139.2, 128.8, 120.1, 115.2, 112.1, 
82.5, 79.6, 65.1, 55.4, 53.5, 52.4, 33.0, 28.0. 
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IR 1736 (s), 1715 (s), 1382 (w), 1276 (m), 1233 (w), 1169 (m), 1048 (w). 
HRMS (ESI) calcd for C19H21NNaO8
+ [M+Na]+ 414.1159; found 414.1181. 
 
Dimethyl-(2R,5R)-2-(4-chlorophenyl)-5-(2,5-dioxopyrrolidin-1-yl)dihydrofuran-3,3(2H)-
dicarboxylate (9d) 
 
 
 
Following the general procedure, using 4-chlorobenzaldehyde (8d) (56.2 mg, 0.400 mmol, 
2.00 eq), dimethyl 2-(4-chlorophenyl)-5-(2,5-dioxopyrrolidin-1-yl)dihydrofuran-3,3(2H)-
dicarboxylate (9d) (71.0 mg, 0.179 mmol, 90 %) was obtained as a colorless oil.  
 
Crude analysis: dr = 14:1 between peaks at 6.36 (minor) and 5.80 (major). 
er = 91:9, Chiralcel IA Hexane/iPrOH 70:30, 1 mL/min, λ = 210 nm, tr1 = 19.5 min; tr2 = 
47.2 min.  
[α]D25.0 41.8 (c = 0.53, CHCl3). 
Rf  0.3 (4:6 Pentane/AcOEt). 
1H NMR (400 MHz, CDCl3) δ 7.47 (d, J = 8.2 Hz, 2 H, Ar), 7.34 – 7.27 (m, 2 H, Ar), 5.84 – 
5.70 (m, 2 H, N-C-H + Ph-C-H), 4.10 (dd, J = 13.2, 10.9 Hz, 1 H, CH2), 3.84 (d, J = 1.2 Hz, 3 
H, OMe), 3.18 (d, J = 1.3 Hz, 3 H, OMe), 2.76 (s, 4 H, CH2 succinimide), 2.38 (dd, J = 13.2, 
5.2 Hz, 1 H, CH2). 
13C NMR (101 MHz, CDCl3) δ 176.1, 170.7, 167.5, 136.1, 134.3, 129.0, 128.1, 81.8, 79.6, 
64.9, 53.5, 52.5, 33.0, 28.0. 
IR 1737 (s), 1718 (s), 1659 (w), 1382 (w), 1278 (m), 1231 (m), 1212 (w), 1168 (m). 
HRMS (ESI) calcd for C18ClH19NO7
+ [M+H]+ 396.0845; found 396.0844. 
 
Dimethyl-(2S,5R)-5-(2,5-dioxopyrrolidin-1-yl)-2-(thiophen-2-yl)dihydrofuran-3,3(2H)-
dicarboxylate (9e) 
 
 
 
Following the general procedure, using thiophene-2-carbaldehyde (8e) (44.9 mg, 0.400 mmol, 
2.00 eq), dimethyl 5-(2,5-dioxopyrrolidin-1-yl)-2-(thiophen-2-yl)dihydrofuran-3,3(2H)-
dicarboxylate (9e) (71.6 mg, 0.195 mmol, 97 %) was obtained as a colorless oil.  
 
Crude analysis: dr > 20:1. 
er = 95:5, Chiralcel IA Hexane/iPrOH 70:30, 1 mL/min, λ = 210 nm, tr1 = 24.4 min; tr2 = 
31.9 min.  
[α]D25.0 75.3 (c = 0.54, CHCl3). 
Rf  0.4 (4:6 Pentane/AcOEt). 
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1H NMR (400 MHz, CDCl3) δ 7.26 (d, J = 2.6 Hz, 2 H, Ar), 6.96 (dd, J = 5.0, 3.6 Hz, 1 H, 
Ar), 6.03 (s, 1 H, Ar-C-H), 5.74 (dd, J = 11.1, 4.9 Hz, 1 H, N-C-H), 4.22 (dd, J = 13.2, 11.1 
Hz, 1 H, CH2), 3.85 (s, 3 H, OMe), 3.33 (s, 3 H, OMe), 2.74 (s, 4 H, CH2 succinimide), 2.39 
(dd, J = 13.2, 4.9 Hz, 1 H, CH2). 
13C NMR (101 MHz, CDCl3) δ 176.2, 170.4, 167.4, 140.1, 127.0, 126.7, 125.9, 79.4, 78.4, 
65.2, 53.6, 52.7, 32.2, 28.0. 
IR 1736 (s), 1716 (s), 1376 (w), 1279 (w), 1169 (w). 
HRMS (ESI) calcd for C16H18NO7S
+ [M+H]+ 368.0799; found 368.0819. 
 
 
Dimethyl-(2R,5R)-5-(2,5-dioxopyrrolidin-1-yl)-2-((E)-styryl)dihydrofuran-3,3(2H)-
dicarboxylate (9f) 
 
 
 
Following the general procedure, using cinnamaldehyde (8f) (52.9 mg, 0.400 mmol, 2.00 eq), 
dimethyl 5-(2,5-dioxopyrrolidin-1-yl)-2-((E)-styryl)dihydrofuran-3,3(2H)-dicarboxylate (9f) 
(74.0 mg, 0.191 mmol, 96 %) was obtained as a colorless oil.  
 
Crude analysis: dr = 14:1 between peaks at 5.58 (minor) and 5.83 (major). 
er = 94:6, Chiralcel IA Hexane/iPrOH 70:30, 1 mL/min, λ = 210 nm, tr1 = 30.2 min; tr2 = 
56.1 min.  
[α]D25.0 14.8 (c = 0.49, CHCl3). 
Rf  0.4 (4:6 Pentane/AcOEt). 
1H NMR (400 MHz, CDCl3) δ 7.43 – 7.36 (m, 2 H, Ar), 7.30 (dd, J = 8.4, 6.5 Hz, 2 H, Ar), 
7.24 (m, 3 H, Ar), 6.76 – 6.51 (m, 2 H, CH olefin), 5.83 (dd, J = 10.2, 5.9 Hz, 1 H, N-C-H), 
5.25 (dd, J = 5.3, 3.1 Hz, 1 H, O-C-H), 3.95 (dd, J = 13.3, 10.2 Hz, 1 H, CH2), 3.85 (s, 3 H, 
OMe), 3.61 (s, 3 H, OMe), 2.72 (s, 4 H, CH2 succinimide), 2.49 (dd, J = 13.3, 6.0 Hz, 1 H, 
CH2). 
13C NMR (101 MHz, CDCl3) δ 176.3, 170.0, 167.2, 136.2, 134.5, 128.6, 128.1, 126.9, 125.2, 
83.0, 80.0, 64.8, 53.5, 53.0, 32.0, 28.0. 
IR 1739 (s), 1717 (s), 1435 (w), 1276 (m), 1231 (m), 1219 (w), 1169 (m). 
HRMS (ESI) calcd for C20H22NO7
+ [M+H]+ 388.1391; found 388.1388. 
 
 
 
Dimethyl-(2R,5R)-5-(2,5-dioxopyrrolidin-1-yl)-2-phenethyldihydrofuran-3,3(2H)-
dicarboxylate (9g) 
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Following the general procedure, using 3-phenylpropanal (8g) (53.7 mg, 0.400 mmol, 2.00 
eq), dimethyl 5-(2,5-dioxopyrrolidin-1-yl)-2-phenethyldihydrofuran-3,3(2H)-dicarboxylate 
(9g) (65.9 mg, 0.169 mmol, 85 %) was obtained as a colorless oil.  
 
Crude analysis: dr = 13:1 between peaks at 6.15 (minor) and 5.79 (major). 
er = 91.5:8.5, Chiralcel IA Hexane/iPrOH 70:30, 1 mL/min, λ = 210 nm, tr1 = 10.3 min; tr2 = 
18.5 min.  
[α]D25.0 21.6 (c = 0.42, CHCl3). 
Rf  0.4 (4:6 Pentane/AcOEt). 
1H NMR (400 MHz, CDCl3) δ 7.40 – 7.07 (m, 5 H, Ar), 5.79 (dd, J = 10.0, 6.1 Hz, 1 H, N-C-
H), 4.65 (dd, J = 11.4, 2.7 Hz, 1 H, O-C-H), 3.83 (s, 3 H, OMe), 3.79 – 3.73 (m, 1 H, CH2 
THF), 3.76 (s, 3 H, OMe), 2.85 (ddd, J = 14.7, 10.5, 4.8 Hz, 1 H, CH2), 2.76 (s, 4 H, CH2 
succinimide), 2.57 (ddd, J = 13.6, 10.1, 6.3 Hz, 1 H, CH2), 2.48 (dd, J = 13.2, 6.1 Hz, 1 H, 
CH2 THF), 2.37 – 2.24 (m, 1 H, CH2), 1.79 – 1.53 (m, 1 H, CH2). 
13C NMR (101 MHz, CDCl3) δ 176.2, 170.3, 167.9, 141.8, 128.6, 128.3, 125.8, 80.8, 79.5, 
63.6, 53.4, 53.0, 33.4, 32.3, 32.2, 28.0. 
IR 1736 (s), 1712 (s), 1436 (w), 1371 (w), 1274 (m), 1168 (m), 1041 (w). 
HRMS (ESI) calcd for C20H23NNaO7
+ [M+Na]+ 412.1367; found 412.1349. 
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